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Abstract 
Objective: The purpose of the study was to develop and validate a noninvasive, easy-to-
use method of determining corpus Iuteum {CL) function. 
MetJwds: This study documented progesterone JeveJs obtained from tampons during 
menses from 18 women. The new method was compared to information obtained on 
analysis of progesterone concentrations from finger-prick bJoodspots. The participants 
also kept daily temperature and Menstrual Cycle Diary@ records for three cycles. 
Results: CL functioning was evident in 28 cycles and nonexistent in 5 cycles as 
determined by bloodspot analysis. There was no statistically significant difterence in 
progesterone concentrations e>..1racted from tampons from functional and non-functional 
cycles (]:>>0.05). Diary assessment revealed functional cycles bad significantly higher 
scores for the following experiences: side breast tenderness, cramps, fluid retention, 
frustration, sleep problems, depression, and breast size (p<0.05). 
Conclusion: Progesterone in menstrual fluid may be an inappropriate marker for JuteaJ 
function but select physical and emotional experiences observed during the menstrual 
cycle may indicate CL function. 
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l .. O Introduction 
1.1 The Menstrual CycJe 
The role of the ovaries in reproductive function has long been established. The 
human ovarian cycle involves cyclical changes which are induced by hormonal 
interactions among the hypothalamus, anterior pituitary, and the ovaries. Two phases 
divide the ovarian cycle. The first phase, called the follicular phase, typically involves 
the selective development of the dominant ovarian foUicle in anticipation of ovulation. 
The luteal phase, the second phase of the cycle, begins immediately after ovulation. This 
phase is characterized by the formation of the hormone-secreting structure called the 
corpus luteum. At· the level of the uterus the hormones secreted during the follicular 
phase promote endometrial regrowth and proliieration (Raine-Fenning et al.. 2004). 
Thus, this phase is often called the proliferative phase. During the luteal phase, the 
endometritm1 experiences higher glandular development and takes on more secretrny 
properties (Franz III. 1988) in preparation for pregnancy. Fittingly referred to as the 
secretory phase, the end of this phase is signaled by the sloughing of the endometrium as 
menses. Collectively, the proliferative and secretory phases makeup what is generally 
called the menstrual cycle (Figure 1 ). For the purpose of this paper, the term menstrual 
cycle will be used. 
1.1.1 The Follicular Phase 
The menstrual cycle lasts an average of 28 days and ranges from 21-36 days 
(Prior, 1996 ). By definition the foUicular phase starts on first day of menstruation and 
1 
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.
7 ~ •• Oral temperature (celcius) r································· ... 
··!""' : Progesterone ·-... 
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Figure 1. The menstrual cycle. The 17 fkstradio1 (pglml) and progesterone (nglmJ) Jines 
show the relative changes in these hormones over the menstrual cycle. The slladed arrow 
at mid-cycle indicates ovulation 
2 
lasts until ovulation (Chabbert Buftet~ et al .• 1998). The tollicular phase is characterized 
by the presence of a cohort of recruited maturing follicles within the ovaries. The 
hormonal environment during the follicular phase~ principally, the presence of the 
anterior pituitary honnone, follicle-stimulating hormone (FSH), promotes the growth and 
development of the 00\..-yte-containing foUicl~ which function to produce a mature 
oocyte ready for release by mid-cycle. GeneraHy only one foHicJe becomes dominant 
and develops into a mature follicle while the others undergo atresia. During the follicular 
phase the granulosa ceHs that make up the foJ!ic.Je proliferate fom1ing severnl layers 
which are surrounded by an outer layer of specialized thecal cells. These two cell-types 
work together, under the influence of FSH and another anterior pituita.Iy honnone~ 
luteinizing hormone {LlJ), to proouce and secrete estradiol The pul~til~ re)eas(: of LH 
and FSH from the anterior pituitacy (Midgley & Jaffe, 1971) is controlled by 
gonadotropin-releasing hormones (GnRH) from the hypothalamus and modulated by 
ovarian steroids (Yen et al., 1972). The levels of secreted FSH and LH are regulated by 
GnRH pulsatility elicited by ex'temai or internal stimuli (Leyendecker & Wildt, 1989). 
Typically, less frequent pulses lead to preferential FSH secretion whereas rapid recurrent 
pulses lead to Ul secretion (McNeilly, 1988). FSH and LH leave the anterior pituitary, 
enter the circulation and travel to the granulosa and thecal cells in the ovary. During the 
follicular phase, LH stimulates androgen synthesis in the thecal cells and FSH promotes 
estrogen synthesis in the granulosa cells (Franz III, 1988) although it has been argued that 
preovulatory estradiol secretion may be independent of gonadotropin regulation, 
specifically by LH (Kor€l1Illan & Sherman, 1973). Th€ two-cell theory of estrogen 
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production states that the androgens synthesized in the ·thecal cells of the follicle are 
transported to the granuJosa cells where they are converted to estrogens (Falck, 1959; 
Ryan & Petro. 1966~ Bjemng~ 1968). Increasing quantities of estradiol aet on the 
hypothalamus and pituitary bringing about a surge in LH that triggers ovuJation 
(Yussman & Taymor. 1970; Korenman & Sherman. 1973). Just prior to ov-ulation, the 
granuJosa ceHs begin to transfonn into lutein ceUs with tire ca{XtCity to produce 
progesterone (Yusstn~n & Taylor, 1970~ WHO, 1980). As a result of the changing 
follicle there is a dip in the JeveJ o:f circulating e$a<fioJ and a slight inc~ in ~ level 
of progesterone before the LH surge (Chabbert Buffet e.t al .• 1998). \Vhen the mature 
oocyte is expeJled from the foUicJe and available for fertilization, the remaining ruptured 
follicle is transformed into a hormone-secreting structure called the corpus luteum (CL ). 
This marks the beginning of the luteal phase. 
l. 1.2 The Luteal Phase 
The luteal phase :is often defined as the time period between the LH peak and the 
day preceding mense.s (Lenton et al., 1984), generally lasting ·12 to '16 days characterized 
by a dominant progesterone presence and a lower but still significant level of estradiol 
(Abraham et al.~ 1972). The CL rapidly becomes highly vascularized within days of 
ovulation due to the guidance of angiogenic factors (Chabbetf Bulfef et al.~ 1 998). Under 
the influence of LH this structure secretes progesterone and estmdiol (Filioori et al~ 
1984), however, some argue that the CL can function independent ofLH (Asch eta/.~ 
1982). Others report a slov.i.ng of LH pulsatility during the luteal phase due to 
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progesterone modulation (Soules et al., 1984), therefore, progesterone likely acts directly 
on the hypothalamus and possibly the anterior pituitary preventing new foJhcuJar 
maturatiotl and ovulation. Tile CL functi<niS tot about two weeks and in the absence of 
pregnancy wiH degenerate within 14 days. The deteriorating CL eventuaJJy fonns a 
fibrous tissue mass called the corpus albicans. The decline in LH during the luteal phase 
may contribute to the demise of the CL (SouJes et al., 1984). The decline in GnRH 
pulsatility, as evident from decreased LH secretion, is known to result in an increase in 
FSH during the Jate luteal phase (SouJes et al, 1984) possibly aJJowing for new foJJicles 
to be recruited at that time. With the involution of the CL comes a <kcline in 
progesterone and estradioJ levels with the resultant sloughing of tbe endometriwn as 
mtmstrual flow. The first qay of menstrual flow is consider~.d the beginning of a new 
cy~l~. 
I .2 Physiological and Behavioural Changes during the Menstrual Cycle 
Associated with the cyclical honnonal fluctuations throughout the menstrual cycle 
are the dynamic, physio]ogical and behavioural changes that occm within a woman. 
Changes in endometrial histology, cervical mucus, and temperature during the different 
phases of the menstrua) cycle have been docwnented extensively and are commonly used 
to detennine cycle phase. Behavioural changes in mood, sleeping patterns, and appetite 
are among numerous psychological parameters that have been studied. 
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1.2.1 Cyclic Changes in Endometrial Histology 
The endometrium, the innennost lining of the uterus,. is composed of a basilar 
layer and a functional layer. During the early follicular phase. the endometrium is thin (< 
2 mm in thickness) due to the desquamation of the endometrial lining at menstruation 
(Strauss Ill & Coutifuris. 1999). Regeneration and desquamation coexist as proliferating 
epithelium has been seen within 36 hours from the onset of menstruation (Nogale:s-Ortiz 
et al.. 1978). As estradiol levels· rise during the late follicular phase, the endometrium 
experiences glandular hyperplasia and an increase in stromal extiacelluJar matrix that 
peaks around the time of ovulation (Clarke & Sutherland. 1990). Estradiol promotes the 
rapid proliferation of epithelial and stromal ceJJs of the endometrium and by mid-cycle 
the endometrium has reached a thickne.'" of 5 mm (Franz lll. 1988). After ovulation~ 
progesterone secreted by the CL initiates secretoty development of the estrogen-primed 
endometrium and edema of the stroma cells and inhibits estrogen-induced cell 
proliferation (Clarke & Sutherland, 1990; Chabbert Buffet et al.~ 1998). By the late luteal 
phase, the endometrium has reached a thickness of 5-6 mm, is bJghJy vasculari~ and 
has accumulated glycogen-rich vacuoles (Strauss nr & Coutifaris~ 1999). This nutrient-
rich environment is necessary for preparation of possible implantation of an embryo. If 
pregnancy does not occur, the CL involutes resulting in a decline in the level of estradiol 
and progesterone. Although the mechani~ms involved In menstruation are not clearly 
understood, the withdrawal of progesterone and estradiol lead to the infiltration of 
leukocytes, matrix metaUoproteinases (MMPs)~ prostaglandi~ and lysosomes (Fraser, 
1999). These are associated with a hypoxic environment and the sloughing of the 
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endometrial lining of the uterus (Fraser~ 1999). Desquamation of the endometrium 
occurs in the superficial Jayers of the endometriwn, gener..uly the compacta and 
spongiosa layers of the functional layer (Nogales-Ortiz et al., 1978). Menstrual effluent 
consists of tissue fragments and bJood and total fluid volume may vary from cycle to 
cycle (Fraser et al.~ 2001). The normal amount ofblood loss averages about 42 ml (range 
of 16.0-65.7 ml) with day 2 being the heaviest day ofbleeding(VasiJenkoet al, 1988). 
1.2.2 Cyclic Changes in Cervical Mucus 
During the follicular phase, when estradiol is at its peak just prior to ovulation, the 
endometrial glands, notabJy the glands in the cervicaJ area, secrete an abundance of 
stretchy, thin mucus (Pommerenke & V1ergiver, 1947, Rarick et al., 1990). This ha..~ 
biological importance in that the mucus strings align along the cervical canal creating a 
channel-like conduit for sperm motility in the direction of the to-be-fertilized egg (Lamar 
et al., 1940). The day of peak mucus discharge is averaged to be day 15 (± 2.6) of the 
menstrual cycle (WHO, 1983) and has been documented to occur 1-2 days prior to the 
basal temperature shift (Pommerenke & Viergiver, 1947). Patterns of mucus discharge 
have been use-d to define the follicular and luteal phases and determine the fertile period 
of the cycle, which was defined as any day before the peak mucus discharge up to 3 days 
after the peak (WHO, 1983). The probability of pregnancy was highest on peak day 
(WHO, 1983; Stanford et aL, 2003). In the latter half of the cycle, under the influence of 
progesterone, the cervical mucus becomes thick and sticky and in effect acts as a barrier 
for spem1 passage through the cervical canal (Lamar et al., 1940; Niaraki et al, 1981). 
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1.2.3 Cyclic Changes in Temperature 
Basal body temperature is also influenced by the cyclical changes in sex 
hormones throughout the menstrual cycle. Body tempemture is reported to be at its 
lowest during the late foHicuJar phase when estrogen is at its highest (Rubenstein~ 1938; 
Stachenfeld et al .• 2000). A small but significant rise in basal (resting) temperature by 
0.2°C-0.5°C occurs during the luteal phase of the menstrual cycle and is not seen in 
anovulatory cycles (V oilman. 1977). This rise starts about 24 hours after ovulation (Franz 
III~ 1988) and about 48 hours after the LH peak (Prior et al.. 1990a) due to the 
thermogenic properties of progesterone (Israel & Schneller. 1950). This temperature rise 
is typically maintained throughout the length of the luteal phase as Jong as progesterone 
levels are elevated. Temperature decrea.<res to baseline values again during the follicular 
phase. It has been suggested that estrogen modifies the tempenrture effects of 
progesterone (Stachenfeld et al.~ 2000). The mechanism for the thermogenic effect of 
progesterone is not clear, however, progesterone may act on areas within the central 
nervous system, such as the preoptic area of the hypothalamus,. which control body 
temperature (Tsai et al., 1988). Warm-sensitive neurons located in the preoptic area are 
inhibited by progesterone which may result in the blockage of heat-loss mechanisms and 
the facilitation of heat-production mechanisms (Tsai et aL, 1988). In rat medial preoptic 
area neurons, allopregnanolone, progesterone~s primary metabolite, enhances y-
Aminobutyric acid (GABA )-mediated transmission, which plays an important role in the 
control of body temperatme (Uchida eta/., 2002). 
1.2.4 Cyclic Changes in Behaviour 
BehavioraJ changes during the nonnaJ menstruaJ cycle have been widely 
documented and numerous studies l1ave investigated the role of cycle phase in this 
phenomenon. Studies have reported cycle-phase related changes in affect showing a 
correlation of negative affect or mood change such as depression prior to and during 
menses (Beumont et al., 1975; Johnson et al., 1995). However, other reports fail to 
reveal cycle-phase related changes in mood (Little & Zahn, 1974; Laessle et al.~ 1990~ 
Sato et al.> 1995) thus chaUenging the commonly beJd assumption that mood change is 
related to menstruaJ phase. 
Generally, women report poor sleep in the late luteal phase and during 
menstruation (Shaver, 2002~ Baker & Driver, 2004). Jn contrast., earlier research reported 
no effects of cycle phase on sleep (Laessle et al.. 1990; Driver et a/., 1996). More 
recently however, sleep quality or duration was shown to be associated with FSH levels 
(Touzet et al., 2002). and lowered estradiol levels in older menstruating women 
(Hollander et al., 200 l) suggesting that menstrual cycle hormones influence sleep 
patterns. 
Appetite (food intake) and food craving have been documented to increase during 
the luteal phase of the menstrual cycle (Dalvit;, 1981; Both-Orchman et al.~ 1988; 
Bancroft et al., 1988~ Johnson et a/.. 1995) and decrease around the time of ovulation 
(Lyons et al., 1989). Energy expenditure increases during the luteal phase and it was 
postulated that this higher expenditure may be related to the increase in food intake 
during the latter haJf of the menstrual cycle perhaps due to the metabolic influence of 
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progesterone (Webb, 1986). Barr et al. (1995) provide confirmatory evidence of a higher 
energy intake in the JuteaJ phase of ovulatory cycles. In that study~ mean energy intake 
was 1259 KJ/d higher during the luteal phase than during the follicular phase (Barr et al., 
1995). However~ some researchers have docwnented two significant peaks in appetite 
just prior to ovulation and menses (Laessle et al.~ 1990), while others fail to detect a 
difference in energy intake throughout the menstruaJ cycle (Fong & Kretsch, 1993). 
Changes in other physical and emotional experiences such as breast tenderness 
(Hale et a/., 2003), fluid retention (Feuerstein & Shaw, 2002), and irritability (Feuerstein 
& Shaw, 2002) have been documented throughout the menstrual cycle. According to 
Magyar et a/. ( 1979), menstrual cycle experiences such as these identify ovulation in 
women with cycles of normal length. If this is indeed true~ then documentation of 
ovulation may be obtained without the a~sistance of the invasive ovulation detection 
methods used today. 
1 3 Menstrual Cycle Abnormalities 
The normal menstrual cycle lasts an average of 28 days and ranges from 21-36 
days (Prior, 1996). An ovulatory meru.-1rual cycle can be descnlled as one that is 
docwnented as having a normal cycle length~ a mid-luteal serwn progesterone threshold 
of 5 nglml and progesterone peak equal to or greater than 14 nglml (Abraham et a/., 
1974; Marinho et a/.> 1982; Petsos et a/., 1985), and a maximal cervical mucus 
stretchiness observation (Rarick et al .• 1990) 12 days or more before the onset of menses. 
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Deviations from this criterion would be considered abnormal The absence of 
menstruation for 6 months or more is called amenorrhea and cydes of length greater than 
36 days are considered oligomenorrheic (Prior. 1996). Luteal phase deficiency (LPD). 
also termed luteal insufficiency, is defined as inadequate CL function (McNeely & 
Soules, 1988) and can occur in cycles of any lengtlL A short luteal phase. a variant of 
LPD, is associated with a luteal phase Jength of ~ll days in duration as determined by 
LH and temperature analysis (Lenton et al., 1984; Jordan et al., 1994, respectively). 
Using quantitative basal temperature (QBT) analysis {Prior et aL, 1990a), a short luteal 
phase is less than ten days (Vollman, 1977). An ano"'Ulatory cycle. which can also occur 
in cycles of any length. is one in which there is no release of the oocyte at mid-(;ycJe thus 
no formation of a CL (Prior~ 1996). Although respecting the differences between these 
two concepts, for the purpose of this paper the tenns ovuJatory cycle and functional CL 
will be used interchangeably as will anovulatory cycle and non-functional CL. 
Menstrual cycle abnonnalities are common among women (Treloar et al., 
1967; Vollman, 1977). Intnrindlvidual variability of cycle length is also found in 
regularly menstruating women (Treloar et al., 1967; Prior et al.~ 1996). Abnormalities in 
the menstrual cycle are more often observed in younger women within the first few years 
after menarche and in older women approaching menopause (Southam &. Richardt, 1966; 
Treloar et al .• 1967; Doring. 1969; Metcalf. 1983). Many studies have docwnented 
anovulation and luteal phase defects including short luteal phase in regularly 
menstruating women using one or more ovulation detection methods (Table I). Luteal 
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Table 1. A selection of studies revealing menstrual cyde abnonnalities in women using various 
ovulation detection methods 
Ovarian Disturbance 
Anovulation 
LPD 
SLP 
Methodology 
BBT 
QBT 
Serum progesterone 
Urinary pregnanediol 
Salivary progesterone 
Endometrial biopsy 
Ultrasonography 
UrinaryLH 
BBT 
Urinary pregnanediol 
Serum progesterone 
UrinaryLH 
Endometrial biopsy 
BBT 
QBT 
Endometrial biopsy 
PlasmaUl 
Anthor(s) 
Jones,l949 
M3fflball, 1963 
DOring, 1969 
Nagata et al., 1986 
Prior et al.,l990b 
Barr et al .• l994a 
Vollman, 1977 
Wathen et al.,. 1984 
Jones. 194-9 
Metcalfe, 1983 
De Souza eta/.~ 1998 
Vnoreoto eta/., 1989 
Jones, 1949 
~etal, 1980 
Petsos et al., 1985 
De Souza et al .• 1998 
Jones, 1949 
Jones. 1949 
De Souza t•t 1.1!., 1997 
De Souza et al, 1998 
Jordanet lll., 1994 
De Souza eta/., 1997 
De Souza et al., 1998 
Jones, 1949 
Davis et al., 1989 
Barr et al .• J 994a 
Jones,.1949 
DOrin& 1969 
Prior et al.. 1982 
Prior et al., 1990b 
Annos et al., 1980 
Smith et al., 1984 
Shennan & Korentll30, 1974a 
Lentonetal., 1984 
BBT. Basal body temperature; LPD. Luteal phase defect; SLP, Sbort luteal pbase; LH., Luteinizing 
bomtone; QBT, Quantitative basal temperature 
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phase defects occur with similar incidence in both infertile women and those with normal 
fertility (Davis et al., 1989). Smith eta/. ( 1984) documented the incidence of short luteal 
phase as 9% tor infertile women and SUA. for women without fertility problems. ln a 
study evaluating the prevention of bone Joss by synthetic progesterone administration,. 
61% of the 73 recruited recreational athletes that reported regular cycles experienced 
either an anovuJatmy cycJe or a cycJe of short luteal phase Jength during hvo 
prescreening cycles (Prior et al.~ 1994). A prospective one year study investigating bone 
Joss in premenopausal women found only 20% of the 66 women participating in the study 
experienced normal menstrual cycles consistently throughout the study period (Prior et 
al.~ 1990b ). The remaining 80% experienc.ed one or more anovulatory cycles, short luteal 
pha..o;;es, or cycles of abnormal length. Although some question the occurrence of 
anovulation in regularly menstruating women (Malcolm & Cumming, 2003), the 
abundance of literature on menstrual cycle function supports the view that menstrual 
cycle abnormalities in women are a real phenomenon. 
1.4 Risk Factors for Menstrual Aberrations 
What causes meru,irual cycle abnormalities in healthy. meru,iruating women? The 
body's r~'])Onse to physical and psychological stressors may influence and be reflected 
through menstrual cycle patterns. Physical training. body weight or changes in body 
weight, and eating behaviour are among a multitude of possible fuctors that may 
l3 
influence the hypothalamic-pituitary-gonadal axis. This influence may be expressed as 
alterations in menstrual cycle functioning. 
L4.1 Exercise 
Research on the effects of exercise on reproductive function has recognized the 
occurrence of menstrual cycle abnormalities in female athletes (Feicht et a/.~ 1978; Dale 
et al .• 1979; Prior et al .• 1982). Teenage swimmers experienced anovulatory cycles and 
short luteal phases and had lower luteal phase progesterone JeveJs compared to age-
matched moderately active controls and adults (Bonen et al., 1981 ). In another study. the 
sampJe prevalence of abnonnaJ ovarian function in twenty-four exercising women was 
48%, while the sample incidence of LPD and anovulation over a 3-month period was as 
high as 79% (De Souza et aL, 1998). The sedentruy controls in this study ovulated 90% 
of the time and had zero inconsistencies between cycles (De Souza eta/., 1998). Blunted 
elevation of FSH during the follicular-luteal transition may have attributed to the high 
frequency of luteal phase defects and anovulation in this study (De Souza et al.~ 1998). 
Alterations in levels of LH, FSH, progesterone, and estradiol resulting in menstrual 
dysfunction have been documented in athletes and untrained women with increasing 
training intensity (Shangold et aL, 1979~ Bonen et al., 1981~ Bullen et al., 1985; Baker & 
Demers~ 1988). Amenorrhea~ anovulation. and short luteal phases were more common in 
runners with longer training runs or more mileage per menstrual cycle (Feicht et al., 
1978; Shangold et al.~ 1979; Prior eta/., 1982), which suggests a relationship between the 
incidence of menstrual cycle abnormalities and the intensity of training. HO\lt'ever, Prior 
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et al. (1990b) found no difference in the number of ovulatory disturbances between 
women training for a marathon, moderately active women, and sedentary controls. In 
addition, De Souza and colleagues (1997) found no relationship between the an1ount of 
training and menstrual disturbances. Vigorous training is unJikely to be the sole cause of 
menstrual disturbances. Sw<lrtz et al. (1981) have shown that amenorrheic runners 
associate more stress with their physical training than do runners with reguJar menses. 
Stress can promote the release of cortisol from the adrenal gland via the hypothalamus-
pituitary-adrenal axis. An association between cortisol and menstrual abnonnaJities may 
exist due to the inht'bition of hypothalamic output by corticotrophin releasing hormone 
(CRH) which in turn may affect pituitaly reguJation of the menstrual cycle (Cbrousos et 
al., 1998). However, Loucks et al. (1998) tound that altered LH pulsati11ty was due to 
low energy availability in exercising women and not the stress of exercise. Shangold & 
Levine (1982) concluded that the best predictor of menstrual dysfunction during training 
was pre-training menstrual pattern and that an individual's weight influenced menstrual 
cycle functioning irrespective of training~ though Bullen et al. (1985) found that weight 
loss compounded the effects of exercise on reproductive function. 
L4.2Weight 
Body weight and weight change have long been associated with menstrual cycle 
functioning. The onset of menarche and the maintenance of menstrual cycles are 
hypothesized to depend on body weight (Frisch & Revelle~ 1970; Frisch & McArthur, 
1974), although it has been argued that the amount of body fut is more important to 
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ovulatory menstrual function (Wentz, 1980). In essence, adolescent girls must reach a 
criticai or minimum weight for height to trigger the onset of menruche (Frisch & ReveJJe, 
1970) and a minimum level of fatness is necessary for normal menstrual functioning 
(Frisch & McArthur, 1974). Menstrual cycle disturbances have been reported in healthy 
women who lose weight through dieting (Lev-Ran. 1974; Kapen et al., 1981; Pirke et al., 
1985; Fichter & Pirke, 1986) and in obese women (Hartz et al., 1979; Friedman & Kim, 
1985). During a 6-week dieting experiment in which 6 to 8 kg ofbody weight was lost 
by the participants, three of the six women who showed pre-dieting ovuJatmy cycles 
experienced anovulatory cycles during the dieting period (Pirke et a/.. 1985). In another 
study, young women experienced a Joss of rnenSL~ within 4 months on an uncontroJJed 
weight-reducing diet (Lev-Ran, 1974). During a 6-month study investigating fut 
distribution and ovulation only nine of fifty-six overweight or obese women experienced 
regular cycles as determined by basal body temperature and serum progesterone (Moran 
et al., 1999). Hartz et al. (1979) reported more irregular cycles of abnormal lengths in 
women who were significantly heavier or more obese than their regularly menstruating 
counterparts. Similarly, Shennan et al. ( 1981 a) reported cycle irregularity in obese 
women during the 7 years after menarche hO\vever this was limited to those obese at age 
18 who thereafter gained 5 lbs or more. 
Dysfunction of the hypothalamic-pituitary-gonadal axis has been observed in 
women who suffer from eating disorders characterized by severe weight loss such as 
anorexia nervosa (Pirke et al., 1919; Henley & Vaitukaitis. 1985). S:imple weight loss. in 
the absence of pathology, has also been shm\'ll to cause disruptions in endocrine function. 
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During a period of weight loss resulting in amenorrhea, the sleep-wake pattern of LH 
secretion during sleep reverted back to pubertal secretory patterns where there was 
enbanced LH secretion (Kapen et al., 1981). When the weight was regained LH 
secretion returned to adult patterns (no sleep-wake LH secretion difference). Similarly~ 
low levels of LH as well as estrogen were reported during the starvation phase in five 
healthy women participating in a 3-week starvation experiment (Fichter & Pirke~ 1986). 
Other reports, ho\\-rever, found no alteration of LH secretion in mild dieting. but, did 
observe a decrease in steroid production (Pirke et al.~ 1985). In ovenveigbt or obese 
women abnormalities in endocrine function have also been reported Obese women have 
been documented to have an excess of androgen JeveJs produced by adipose tissue 
(Friedman & Kim, 1985~ Unzer et al., 1995). This hyperandrogenemia may indirectly 
cause the increase in LH through elevated levels of estrone, an estrogenic honnone. 
Estrone through its influence on the aromatizing system in adipose tissue causes shifts in 
LHJFSH and testosterone/estradiol ratios that may contribute to anovulation (Unzer et al.~ 
1995). Seemingly paradoxically, reduction of weight has resulted in the return of normal 
menstrual cyclicity and fertility in obese women (Bates & Whitworth, 1982; Haria.,.., et 
al .• 1984). 
1.4.3 Eating Behaviour 
Women with a restrained eating style (i.e. conscious limitation of food intake) 
have experienced abnormalities in reproductive function without . weight change 
(Schweiger et al., 1992). Out of thirteen less restrained eaters, only 2 women bad 
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abnormal menstrual cycles. Out of the highly restrained eaters only 2 of 9 women had 
nonnal cycles (Schweiger et al, 1992). Low progesterone concentrntions, fewer 
ovulatory cycles, and/or shorter luteal phase lengths bave been documented in women 
scoring high for restrained eating (Schweiger et al, 1992; Barret al, J994a; Barret a/., 
1994b) providing evidence of an association between dietary restraint and ovulatory 
function. However, the reduction in caloric intake in restrained eaters comJXlflX{ to 
unrestrained eaters has not ahvays been documented as significant (Barr et al., 1994b) or 
accurate {SchoeJier et al .• 1990). 
Nonetheless, it has been postulated that the decrease in progesterone IS a 
compensatory reaction to the reduction in caloric intake and energy expenditure in 
restraine.d eaters (Schweiger et al.~ 1992). More recently it bas been shown that low 
energy availability alters LH secretion (Loucks et al, 1998) which in tum may shape the 
menstrual pattern. Mclean and colleagues (2001) found higher 24-h urinary cortisol 
excretions in women scoring high for food restraint These authors speculate that women 
who score high for restraint may be experiencing higher stress than those scoring low for 
restraint (Mclean et al., 2001). The heightened CRH release in these women may have 
an inhibitory impact on the hypothalamic-pituitary-gonadal axis thus interfering with the 
menstrual cycle (Chrousos et al .• 1998). 
1.4.4 Summary 
Exercise, absolute weight or modest fluctuations in body weight and eating 
behaviour may trigger changes in the hypothalamic-pituitary-gonadal axis resulting in 
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ovulatory disturbances. Not all obese, underweight, athletic, or dietary conscious women 
experience menstrual cycle abnormalities. Thus the sensitivity of the endocrine system to 
physical, hormonal, nutritional, and psychological factors may vary from individual to 
indi\<idual and perhaps from cycle to cycJe. 
1.5 Health and the Menstrual Cycle 
Whatever may be the cause of menstrual cycle abnormalities in women, the more 
critical .issue is the effect of these disturbances on the weJJ-being of the individual 
Irregularity of the cyclical hormonal milieu driving the menstrual cycle may play a 
significant role most obviously in reproductive function but also in other bodily systems. 
The interplay of steroid hormones throughout the body is es...c.;ential for optimal bodily 
function. Therefore~ abnormalities within the reproductive system stemming from 
peripheral or central origin may have effects in other areas of the body tbat are influenced 
either directly or indirectly by the hormonal changes related to the menstrual cycle. 
1.5.1 Infertility 
The most apparent outcome of meru;trual disturbances is infertility - the inability 
to conceive a child or the inability to sustain a pregnancy. Although the etiologic factors 
of infertility may be multiple, menstrual cycle abnormalities are observed in infertile 
women. Anovulation is the most obvious cause of infertility; without the release of an 
oocyte there can be no fertilization. Anovulation along with hyperandrogenemia are the 
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most common causes of infertility in massively obese women (Friedman & Kim. 1985). 
Endometrial biopsy of 1022 patients with primary infertiJity showed anovuJation in 
12.6% of women (R.ameshkumar & Thomas, 1991). However, in patients with either 
primary or secondary infertility inadequate CL function was the most frequently observed 
menstrual cycle abnormality. Follicular and ovulatory disturbances occurred less often 
(Jones, 1949). Thus, when ovulation did occur either progesterone secretion by the CL 
was not enough to prepare the endometrium for maintenance of a pregnancy or the 
endometrium was unable to respond to the secreted progesterone. For example~ in some 
cases urinary pregnanediol levels were normal but endometrial biopsy showed a 
nonsecretory endometrium (Jones, 1949). Menstrual cycles of short Juteal length are 
suggested to be a common form of infertility in women. This is pos..c;fu1y due to deficient 
FSH secretion resulting in insufficient follicle maturation leading to the derivation of an 
inadequate CL (Sherman & Korenrnan, 1974a). However, if short luteal phase is 
associated with infertility, then infertile women might be expected to have a higher 
:Incidence of this form of luteal phase defect This was not observed in a study by Smith 
et al. ( 1984) who found the incidence of short luteal phase to be 8% and 90/o respectively 
in a group of normal and infertile women. As cycles of short luteal length are also found 
in women without fertility problems (Smith et al., 1984), and serum progesterone levels 
were greater than 2 SEM below normal in all infertile women with short luteal phase 
length studied by Shennan & Korenman ( l974a), it is not necessarily the length of the 
luteal phase but ultimately the adequacy of steroidogenesis that is the major &ctor in 
infertility. In support of this, an infertile patient with consistent insufficient luteal 
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function was able to carry her pregnancy to term with progesterone therapy (Jones & 
Madrigal-Castro, 1970). Endometrial inadequacy is an entity associated with infertility 
that is usually caused by luteal abnonnalities and can be treated with progesterone 
therapy (Moszkowski et al., 1962). 
1.5.2 Breast Cancer 
Epidemiological studies have identified reproductive events as risk factors for the 
development of breast cancer (KeJsey, 1979~ Sherman et al .• 1981b). HistoJogicaJ and 
morphological changes of the human breast correlate with menstrual phase (Vogel et al., 
1981~ Battersby et aL. 1992; Ramakrisbnan et al .• 2002) Jeaving JittJe doubt that breast 
tissue is sensitive to fluctuations in hormones as...wated with the menstrual cycle. The 
action of progesterone on alveolar cells and lobular development within the breast has 
been generally descnbed as proliferative causing a transient swelling of the breasts. 
Chang et al. ( 1995) describes this action as short-te~ the long term ( 10-13 days) action 
of progesterone being anti-estrogenic~ reducing estrogen-induced mitotic activity within 
the breast. Down-regulating estrogen receptors by progesterone (Battersby et a/., J 992) 
will influence the epithelial cell cycle and perhaps preventing breast epithelial 
hyperplasia, a risk fru.."1or for breast cancer (Page et al., 1990). The presence of estrogen 
and progesterone receptors within the breast (Battersby et al.. 1992; Atalay et al .• 2002) 
indicates that this organ is a target of the hormonal action of these two steroids. Thus, it 
can be assumed that during altered honnonal conditions responsible for menstrual cycle 
abnormalities, the breast will be subject to the consequences of the same disorder. In a 
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prospective study investigating the incidence of breast cancer in infertile women. those 
with a history of progesterone deficiency had 5. 4 times the risk of developing 
premenopausal breast cancer compared to women treated for non-hormonal-based 
infertility (Cowan et al., 1981 ). As weU, the women with persistent progesterone 
deficiency were 10 times more likely to die from malignant neoplasms compared to the 
hormone sufficient group (Cowan et al .• 1981). Bulbrook et al. (1978) found a 
correlation between sub-normal luteal phase plasma progesterone levels and increased 
risk of breast cancer in premenopausal women. Those with higher risk charac1eristics for 
breast cancer such as earlier age at menarche, a family history of breast cancer, later age 
at first parity, and lower urinary aetiochoJanoJone excretion (due to its reflection of 
progesterone levels) had a diminished level of progesterone in the luteal phase and more 
anovulatory cycles compared to those with lower or no risk: factors (Bulbrook: et aL, 
1978). Early menarche and late menopause have been associated with increased risk of 
breast cancer (Staszewski, 1971; Trichopoulos et al., 1972) possibly due to the exposure 
of a lengthened reproductive life time to the incidence of abnormal menstrual fimction 
(Shennan & Korenman, 1974b). Late age at first pregnancy and nulliparity have also 
been linked to an increase risk of brea..~ cancer (Lowe & MacMahon~ 1970). Sherman 
and Korenman (1974b) interpret these reproductive breast cancer risk fal.1.ors as 
manifestations of an inadequate CL. In support of thi~ Grattarola (1964) found secretory 
endometrium during the luteal phase in 67. JOA, of nonnal premenopausal women but only 
in 17.2% of premenopausal breast cancer patients. Women with benign breast disease 
have lower than normal progesterone concentrations during the luteal phase (Sitruk-Ware 
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et al., 1977). Breast cancer patients show similar patterns of luteal deficiency (Swain et 
al .• 1974; Kodama et al, 1977). These luteal phase abnoimalities may reflect abnoimal 
menstrual functioning during the earlier reproductive years in these women. Thus, these 
results are consistent with a role of altered ovarian hormone production in disease. 
Specifically. unopposed estrogen levels in the face of diminished progesterone 
concentmtions have been implicated in the development of breast cancer and other 
malignancies. 
Swain et al. (1974). however, found luteal deficiency only in women with 
advanced breast cancer and no increased incidence of ovulatory failure or decreased 
progesterone concentrations in early-stage breast cancer patients when compared to 
controls. Similarly, McFayden et al. (1976) found no evidence of abnonnal honnone 
concentrations in women with breast cancer whereas other groups have found iUCTeased 
levels of estradiol and progesterone in premenopausal women with benign or malignant 
breast disease (England eta/.~ 1974; Skinner et al.~ 1975). Coulom et al. (1983) reported 
that the risk for breast cancer in women with chronic anovulation equaled that of the 
geneml population. Thus, more research is needed to re-evaluate the relationship 
between menstrual cycle endocrine function and the risk for developing breast cancer. 
1.5.3 Endometrial Cancer 
Endometrial cancer has similar reproductive risk factors as breast cancer (Kaaks 
et al., 2002). As Martel and Sommers (1957) observed, endometrial and breast adenoma 
often occur in the same individual. Associations among early menarche (Kaaks, et al., 
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2002), late menopause. late age at frrst pregnancy (Salazar-Martinez et al., 1999), 
nuJJiparity (Shu, et al., 1991) and increased risk of endometrial cancer have been 
reported. However. some of these associations bave not been corroborated (Henderson et 
al., 1983; Salazar-Martinez et al.,. 1999). 
Infertility caused by chronic anovulation increases the risk of endometrial cancer 
3-fold (Coulam et al., 1983). Escobedo et al (1991) investigated the relationship 
between endometrial cancer and infertility and concluded that risk. for endometrial cancer 
may be Jimited to long-tenn infertility (>2 years) and women with infertility-associated 
conditions such as polycystic ovary syndrome (PCOS). Shu et al (1991) bas also 
reported an association between increased risk for endometriaJ cancer and PCOS as weU 
as obesity. Women with endometrial cancer before the age of tbrty often have a pa..crt 
reproductive profile of menstrual irregularities, infertility and PCOS (Fox. 1976). In 16 
endometrial cancer patients aged 19-35 years old. amenorrhea, sterility, obesity or 
menorrhagia (abnonnally heavy or extended menstrual flow) were reported (Sommers et 
al.~ 1949). Also these patients were more likely to have hyperplasia or fibrosis of stromal 
cells and luteinization of thecal celts. These findings are indicative of abnonnal 
endocrine stimuli and responses which may potentially play a role in the pathogenesis of 
the disease. 
The unopposed estrogen hypothesis is the principal theory used to explain the 
association between endocrine functioning and the development of endometrial cancer 
(Siiteri, 1978; Key & Pike. 1988). During the follicular phase, estrogens activate mitotic 
activity in endometrial cells which is cotmterbalanced by the anti-proliferntive effects of 
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progesterone in the luteal phase (Key & Pike, 1988). Progesterone does this by reducing 
estrogen receptors within the endometriwn and by inducing estradiol-metabolizing 
enzymes such as estradiol dehydrogenase and sulfotransferase which convert estradiol to 
the Jess active estrogen, estrone (Siiteri, 1978; Clarke, Adams, & Wren, 1982; Key & 
Pike, 1988). Thus, in progesterone deficient cycles, the mitogenic effects of estradiol are 
unopposed creating a continuous proliferative state within the endometriwn which may 
lead to the development of cancerous tissue. In a prospective study, Modan et al. (1998) 
found a high rate of endometrial cancer in infertile women with unopposed estro&'en 
status (i.e. progesterone deficient group). In support of this, women taking estrogen-only 
oral contraceptives or estrogen replacement therapy (ERT) ha-v--e been reported to be at 
high risk for developing endometrial cancer whereas women taking a combination-type 
pill of estrogen and progestogen show decrea.cred risk for developing the disease 
(Henderson et al., 1983; Key & Pike, 1988; Shu et al., 1991~ Kaaks eta!., 2002). 
Lifestyle factors such as obesity increase the risk for developing endometrial 
cancer (Shu et a/., 1991) and women with this disease are often of heavier stature 
(Sommers et al.~ 1949; Austin et aL~ 1991). Obesity ha~ been associated with menstrual 
and hormonal abnormalities (Hartz et al., 1979; Unzer et a/., 1995). Overweight 
premenopausal and menopausal women have lower than nonnal levels of sex hormone 
binding globulin (SHBG) and higher than normal levels of androstenedione and 
testosterone, and in menopausal women only, estradiol (Harlass et al.~ 1984; Kaaks et al., 
2002). In premenopausal women this profile contributes to the increase in bioavailable 
ovarian androgens leading to owlatory failure and progesterone deficiency (Batbieri et 
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al., 1988; Unzer et al .• 1995). It is not surprising then that obese women and women with 
PCOS, which is characterized by ovarian hyperandrogenism, reduced SHBG, chronic 
anovulation, and often obesity (Barbieri et aL, 1988), are at increased risk of developing 
endometrial cancer (Austin et al., 1991; Shu et al, 199 J ). Thus in premenopausal 
women, endometrial cancer risk is associated more with progesterone deficiency rather 
then higher estrogen levels. In menopausal women, however, excess weight is related to 
an increase in bioavailable estrone and estradiol due to the peripheral conversion of 
androstenedione to estrone and then estrone to estradiol (Kaaks et al, 2002). Thus, in 
menopausal women increased risk of endometrial cancer is related to an elevation in 
bioavailable estrogens. 
1.5. 4 Bone Health/Osteoporosis 
Bone loss and menopause are often linked Estrogen deficiency due to the loss of 
ovarian function contributes to osteoporosis in menopausal women (Albright et al, 1940; 
Albright et al., 1941; Slemenda et al., 1987). Estrogen therapy decreases bone loss by 
preventing or slowing bone resorption (Snow & Anderson, 1986). Furthermore, bone 
turnover is increa.c;ed when estrogen levels fall (Carr et al., 2003). Circulating 
progesterone levels also decrease at menopause. Progesterone action promotes bone 
formation and regulates bone turnover (Prior, 1990). Menopausal women treated with 
combination estrogen and progestin therapy showed increased bone mineral density 
(BMD) and reduced risk of fiacture at the hip~ vertebrae, and 'Wrist (Cauley eta/., 2003). 
One year of cyclic medroxyprogesterone treatment increased spinal bone density in 
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active premenopausal women who experienced menstrual disturbances (Prior et al.. 
1994). 
In vitro studies have shown that progesterone competes with synthetic 
glucocorticoid binding sites on osteoblasts (bone fonning ceUs) antagonizing the 
resorptive effects of glucocorticoids (Yoshioka et al., 1980 ). Other studies have 
demonstrated direct anabolic effects of progesterone on the stimulation of bone ceJJ 
proliferation in human osteoblast cell cultures (Tremollieres et al., 1992). Ovariectomy 
in rats resulted in a decrease in progesterone-dependent osteoprogenitors in vertebral and 
femoral cell populations wllile treatment with estrogen and progesterone increased 
progesterone receptors in vertebrnl cell populations (Pei eta/., 1999, Pei eta/., 2003). 
Receptors specific for estrogen and progesterone have been identified in human 
osteoblast-like cells (Eriksen et al., 1988; MacNamam et al., 1995) suggesting a direct 
role of these hormones in bone metabolism. Therefore, a reduction in estrogen and 
progesterone levels at menopause may be involved in the uncoupling of bone formation 
to bone resorption resulting in net bone loss leading to osteoporosis in menopausal 
women. 
Studies have shown that bone Jos.s occurs in menstruating women of 
premenopausal age (Prior, 1990) and that reproductive status or alterations in the 
hormonal milieu of the menstrual cycle may be a determinant of current and future bone 
health (Drinkwater et al.~ 1990; Prior et al., 1990b; Prior etal.~ 1994, Prior eta/., 1996; 
Cooper and Sandler, 1997, Sowers et al., 2003). In a cross-sectional study of70 healthy 
women, bone loss of the lumbar spine was determined to decrease by 44% from the age 
27 
34 throughout life (Kreiner & Pors Nielsen, 1982). The rate of bone loss accelerates 
immediately after menopause. Prior et al ( 1990b) cmrelated decreased bone density 
with subclinical ovulatory disturbances in 66 premenopausal women, aged 20-42 years,. 
studied over a 12-month period. These authors found a significant decrease in bone 
density in women experiencing short luteal phases and anovulatory cycles in which 
progesterone was deficient. Bone density was maintained in women who experienced 
normal ovulatory cycles consistently throughout the year however. as a whole. the mean 
decrease in bone density in all participating women was 2.0% per year (Prior et aL~ 
1990b). A follow-up study showed au association between ovulatory disturbances 
initiaiJy docwnented in the first year and the rate of bone Joss over a five year assessment 
(Prior et al., 1996). In the same group of women, those in the tower tertile of luteal 
length tended to lose bone whereas. those in the upper tertile of luteal length were 
protected from any loss in bone density (Petit et al., 1999). In a group of progesterone 
deficient women treated for l-year with medroxyprogesterone or placebo, spinal bone 
density of those in the placebo group signific-antly decre.ased while women treated with 
medroxyprogesterone showed increased bone density (Prior et al.~ 1994). These results 
underscore the importance of progesterone in preventing hone loss and improving bone 
integrity. 
Despite this evidence, some studies dispute an association between luteal 
abnormalities and changes in bone density (Waller et al.~ 1996~ De Souza, et al .• 1997; 
Bemben et al., 2004}. Bemben and colleagues (2004) found no significant effect of 
menstrual status on bone mineral density in young women athletes, however~ 
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eumenorrheic women tended to have higher bone density than those who experienced 
oligomenorrhea or amenorrhea. In this study. gymnasts reported more menstrual 
disturbances but had significantly higher bone density compared to cross-country runners 
indicating that the type of mechanical Joading can mitigate the effects of the bonnonaJ 
environment. De Souza et al. ( l997) argued that a reduction in estradiol and not 
progesterone was the cause of bone loss in femaJe runners and that bone density is 
unaffected by progestemne deficient luteal phases as long as estradiol levels are 
adequate. Other studies, hmvever, have failed to associate estradiol with chan!:,'eS in bone 
mineral density (Sowers et al., 2003~ Bemben et al., 2004). Waller et al. (1996) did not 
find an association between bone density and either Juteal phase length or progesterone 
(urinary pregnanediol). A slightly significant decrease in whole body bone density was 
seen with increa.-;;ed cycle length, but no significant decrease in bone density was noted 
with decreasing luteal function (Waller et al., 1996). Petit eta/. (1996~ 1998) have 
questioned several methodological aspects of the studies by De Souza et al. ( 1997) and 
Waller et al. (1996). Adequacy of the detection methods of bone measurement. type of 
bone assessed, adequacy of ovulatory assessment, and timing of ovulatory assessment 
relative to bone assessment are an critical fuctors. Indeed, more re..~rch and standard 
research methods are needed to confirm potential relationships between menstrual and 
ovulatory disturbances and bone health. 
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1.6 Ovulation Detection Methods 
The incidence of anovulation and short luteal phases differs among the many 
studies investigating menstrual cycle abnonnalities. For example, Nagata et al. (1986) 
and Prior et a/. (I 990b) have documented the incidence of menstrual cycle abermtions as 
high as 64.9(% and 80.3%, respectively. Waller et al. (1996) and Malcolm & Cumming 
(2003), on the other han<L have reported the prevalence of reproductive abnoimalities to 
be much fewer among eumenorrheic women (5.1% and 3.?0/o, respectively). More than 
likely this disparity lies with the difference in study methods as weJJ as design, i.e. 
longitudinal versus cross-sectional studies. Several methods are used to predict or detect 
ovulation in women. Methods include LH testing, basal body temperature recordings, 
serum progesterone measurement, endometrial biopsy, and ovarian ultrasonography. 
1.6.1 LH Testing 
Ovulation occurs between 8-40 hrs after the plasma LH peak (WHO, 1980). 
therefore, increased LH concentrations are often measured to predict ovulation. The 
fuilure to detect a significant rise in LH levels has been u._c;ed as a criterion for anovulation 
and cycle abnormalities (Tab1e J ). Colorimetric horne kits have been made available 
whereby LH is measured in the urine by monoclonal anti-body-based enzyme 
immunoassay di~'tick test kits in which color intensity estimates LH concentration 
(Elkind-Hirsch eta/., 1986). These kits have been deemed clinically reliable by some 
(Elkind-Hirsch et al., 1986; Vennesh et al., 1987) but questionable by others (Lloyd & 
Coulam, 1989). In the study by Elkind-Hirsch et a/. (1986) the UI surge was associated 
30 
with basal temperature and serum progesterone in all cycles assessed, however, when 
compared with ultrasound the LH test was Jess reliable. Uoyd and CouJarn ( 1989) 
documented the rise of LH after follicle rupture in 90.4. of cases as measured by 
ultrasonography. Anovulation has been dociunented in cycles in spite of the presence of 
a LH surge (McNeely & Soules, 1988). In this case, additional means of assessing luteal 
function were vvarranted LH testing ·whether measured in serum or urine requires several 
days of testing and often more than once daily (Elkind-Hirsch et al., 1986) which can 
make the process tedious and inconvenient 
1.6.2 Basal Body Temperature Recordings 
Progesterone elicits thermogenic changes during the 1utea1 phase (Israel & 
Schneller, 1950). As the rise in temperature during the second half of the cycle is 
indicative of luteal function, it is commonly used as an easy and inexpensive surrogate 
method of detecting ovulation in women. Jones (1949) described basal temperature 
charts as the most sensitive indicator of CL function. A biphaslc temperatme pattern 
during the menstrual cycle is correlated with ovulation (i.e. luteal function) whereas a 
monophasic pattern is associated with anovulation or no evidence of luteal function. 
Temperature recordings have been used for years as a method of determining menstrual 
status (Table I). 
Some consider basal body temperature recordings to be unreliable and inaccurate 
(Lenton et al., 1977). ln a study by Moghissi (1976) where ovulation was docmnented by 
hormonal analysis of E2, LH, and progesterone, 20% of women participants bad 
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monophasic temperature patterns indicative of anovulation. Studies by Johansson et al. 
(1972) and Hilgers and Bailey (1980) have fom1d that basal body temperature cwves 
have led to the unreliability of analyses in 12% and 6.8010 of cycles examined, 
respectively. Some researchers have concluded that the presence of a monophasic 
temperature patterns is not sufficient to determine anovulation (Johansson et al.~ 1972). 
Thus, other determinants of ovuJation are required in addition to temperature. 
In the past,. many experimental subjects were required to plot and chart their own 
temperature (Marshall, 1963). Charts have been analyzed visually giving a 
nonquantitative interpretation of temperature data (Morris et al.~ 1976; Hilgers & Bailey, 
1980). These as weU as a number of other issues such as the time of temperature taking 
and errors in reading thermometers have been c.onsidered problems that may compromise 
the reliability of temperature methods in determining menstrual statu,., (Prior et al., 
1990a ). To resolve these problems, Prior et al. (1990a) validated a quantitative basal 
temperature (QBT) analysis method against the midcycle LH peak in which ovulation 
and luteal phase lengths can be determined using a least mean square method of analysis 
(Maximina® Quantitative Basal Temperature Analysis Program). The participants were 
instructed how and when to take their temperature and to note any situations out of the 
ordinary such as sleeping in that may have affected their temperature. Using the least 
mean square criteria~ a significant increase in temperature is used to determine the on..c;et 
of the 1utea1 pha')C, and this is suggestive of ovu1ation (Prior et aL.,. 1990a). This 
computer program has been used in the present study. Similar accuracy and reliability 
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were obtained with the mean temperature method (Vollman, 1977) and QBT (Prior et al.~ 
1990a). 
1.6.3 Serum Progesterone Me&"""Ufements 
The CL secretes progesterone during the luteal phase of the menstrual cycle thus 
progesterone measurements in serum can be and are often used as the "gold standard" 
when evaluating CL function in women (Table 1 ). Thus~ low JuteaJ phase progesterone 
would suggest menstrual cycle abnommlity (van Zomrevel~ te Velde, & Koppescbaar~ 
1994) whether it is anovuJation or CL dysfunction. Jordan et al (1994) recommended a 
single midluteal serum value greater than 10 nglml or the sum of three serum values 
greater than 30 nglml as the best test for nonnal luteal phase function. However, 
progesterone concentrations are pulsatile and highly variable during the luteal phase 
(Soules et a/.. 1988) thus the timing of progesterone measurements stiU remains 
problematic. Therefore. several serum or urine samples would be necessary to make a 
proper assessment of luteal function. Progesterone measurements obtained via 
venipuncture or through urine collection can be considered by some to be invasive, 
uncomfortable, and inconvenient (E1kind-Hirsch et al., 1986; McLough1in et al ... 1994). 
Furthermore, ascertaining their timing requires knowing the dates of onset for both the 
preceding and subsequent meru,"'trual cycles. 
An alternative to venipuncture is finger-prick blood sampling (McLoughlin et al.. 
1994). This method requires only a few drops ofblood pricked from the finger and 
collected on filter paper cards. Progesterone concentrations measwed .from finger-prick 
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blood samples has been highly c.orrelated with progesterone concentrations from serum 
samples (r = 0.98~ Petsos et al., 1985; r = 0.98, Petsos et aL, 1986; r = 0.997, McLoughlin 
et al., 1994; r = 0.98, Shirtcliff et al., 2001). Bloodspot progesterone concentrations can 
thus be converted to serwn equivaJents using linear regression coefficients. There are 
many advantages to using bloodspot sampling. Firstly, they are useful for diverse study 
designs such as cross-sectional swveys and longitudinal and epidemiological studies that 
often require serial sampling over long periods of time and/or sampling of large 
populations (Worthman & Stallings, 1997). Bloodspot filter cants yield easy and long-
time storage. Bloodspot cards can be stored up to 9 and 15 weeks at 25°C and 37°C, 
respectively, and nine months at moderate tempe:mtures with Jittle degradation in steroid 
hormones (Howe & Handelsman, 1997). When frozen, bloodspot samples are stable for 
at least a year (Worthman & Stallings, 1997). Lastly, bloodspot sampling is minimally 
invasive, convenient, and can be performed by the subjects themselves; bloodspot cards 
are easily transportable and because the blood sample is dried on the card, viruses such as 
hepatitis and HIV are killed which lowers a potential biohazard risk (Worthman & 
Stallings, 1997). Bloodspot sampling was used in the present study. 
1.6.4 Endometrial Biopsy 
Not withstanding Jones' (1949) view that temperature change is the most 
sensitive test of CL function~ be maintains that endometrial biopsy analysis is the most 
sensitive test of luteal adequacy. When assessing CL functio~ endometrial biopsies are 
often obtained during the late luteal phase and timed by temperature recordings,. LH 
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surge, or ultrasound scanning. Endometrial biopsy can be useful for detecting the 
presence (or absence) of secretmy endometriwn indicating a functional CL (or CL 
dysfunction) (Table 1). A luteal phase defect is predicted when the endometrium is out-
of-phase by at least two days such that there is a discrepancy between the observed 
endometrium and the expected endometrial pattern (Annos~ Thompso~ & Taymor, 
1980). Endometrial biopsy results have been coueJated with luteal phase progesterone 
levels (Nadji et al., 1975). Annas, Thompson, & Taymor. (1980) however. have shown a 
50% discrepancy between these two pammeters suggesting that one does not obviate the 
need for the other. Disparities among progesterone 1eve~ endometrial biopsy 
assessments and temperature data analysis may be due to the failure of endometriwn to 
he stimulated by progesterone action (Jones, 1949; Shangold et al .• 1983). Jordan eta/. 
( 1994) concluded that the sensitivity and specificity of endometrial biopsy wa."> marginal 
in the diagnosis of luteal phase defects. In addition, Li et al. (1987) reported a low 
correlation between the interpretations of two experts (r = 0.70) making observer 
subjectivity problematic. Endometrial biopsy may also precipitate early menses which 
may shorten luteal phase length (Annos el al.~ 1980). This procedure is invasive and the 
problem of proper timing of the biopsy remains un..c;olved 
1.6.5 Ultrasonography 
Ultrasonography is a relatively direct method used for the prediction and 
detection of ovulation. The prediction of ovulation is based on follicle size and detection 
is based on the abrupt disappearance or collapse of the follicle (Marinho et al., 1982). 
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Ultrasound scanning has been used to visualize follicle growth (O~Herlihy et al.~ 1980) 
and the development of the CL indicating ovulation (Queenan et al., 1980). This method 
is also useful in revealing menstrual cycle abnormalities (Table 1 ). In a study by 
Vennesh et al. (1987) ovulation as detennined by ultrasonography foJJowed LH peak for 
every cycle. However, the development and collapse of a dominant follicle ( 18-25 mm in 
size) as visualized by ultrasonography does not always prove ovulation (Queenan et al, 
1980; Petsos et al., 1985). Used alone, ultrasonography may not be sufficient Other 
studies have observed premature ovulation during the Jate foJJicular phase in women after 
the ultrasonography procedure (Testart et al., 1982). Ultrasound scanning also requires a 
trained operator, several days of testing. is invasive (vaginal penetration) and expensive 
(Marinho et al., 1982). Thus, ultra...~nography is not practical for large-scale population 
studies. 
1.7 Purpose of Present Study 
The purpose of the present study is to develop and validate a noninvasive, easy-
to-use method of determining CL function in women. The Jack of standardized test-; to 
detect menstrual cycle abnonnallties makes it difficult to document the variability of 
menstrual cycle function among women. These ovarian disturbances can be a result of 
stress, weight loss or gain, illness and intense exercise or a combination of these factors 
(Prior, 1985). Previous research has associated ovarian disturbances with bone loss with 
attending risk for osteoporosis (Prior eta/., 1990b; Prior et al .• 1994). Women with a 
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history of ovulatory defect~ specifically progesterone deficiency,. are more at risk for 
breast cancer (Cowan eta/., 1981) and women experiencing chronic anovulation may be 
at higher risk for certain cancers such as breast cancer and endometrial carcinoma 
(CouJam et al. 1983). However, more research and better research methods to 
document menstrual cycle hormonal characteristics are necessary to confirm these 
findings in prospective studies. The proposed study aims to develop such a method 
Current ovulation detection methods are variably reliable~ tedious, invasive, 
and/or expensive (See section 1.6). Timing of tests for documentation of appropriate 
hormonal changes is difficult due to varying cycle lengths and the absence of a clear 
clinical marker of the appropriate timing within the cycJe. This study proposes to 
document the progesterone levels obtained from tampons during menses to overcome the 
major problem, which is timing the sample appropriately. Measurement of sex honnones 
such as progesterone is useful in determining luteal function. Receptors for estradiol and 
progesterone in the endometrium (Haukkamaa & Luukkainen, 1974; Rao !-~ al., 1974; 
Janne et al., 1975; Flickinger et tll., 1977) concentrate these hormones. During menses 
the endometrium is shed and the shed tissue should contain these honnones. 
Hormones can be extracted from used sanitary products {Hofer et al .• 1993; 
Bieglmayer et al., 1995; Peddle [Hons Diss], 1996). Several studies have measured 
prostaglandin levels in menstrual fluid collected on tampons to examine its relationship to 
dysmenorrhia (painful menstruation) in women (Chan & Hill. 1978; Powell et al., 1985; 
Hofer et al., 1993; Bieglmayer et al., 1995). Zhou et al. (1989) measured reproductive 
hormones in peripheral blood samples and menstrual fluid samples collected in silicone 
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rubber menstrual cups. Peripheral blood and menstrual fluid collected on days 1-3 of 
menses were centrifuged and the plasma assayed Mean progesterone concentrntions 
were less than 1 nglml for both peripheral and menstrual samples and no correlation was 
found between the progesterone measurements (Zhou eta/., 1989). These authors did not 
demonstrate the ovulatory status of the women participants. 
Studies that have examined menses as an indicator of ovuJation or luteal function 
are limited. Peddle (1996) developed a method to extract progesterone from doped and 
participant used tampons using a Sep-Pak C 18 Classic cartridge. The results were 
variable and the amount of progesterone recovered from participant used tampons was 
low ( <2 ng/tampon). Neither serum honnone leveJs nor basaJ temperature were 
measured at any time prior to menses thus menstrual status was not as...'\eSsed in the 
participants. 
The method in the present study \\>ill be compared to information obtained on 
quantitative assessment of serial daily basal temperature measurements (Prior et al., 
1990a), and analysis of progesterone concentrations from blood spots obtained after 
finger prick, which will act as the ''gold standard'' (Pet()()s et a/., 1986). Potentially this 
new method could be used cycle by cycle over many years to advance our understanding 
of menstrual cycle variability. 
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2.0 Materials and Methods 
2. l Participants 
Women responded to an advertisement to participate in a study about ovarian 
function and menstrual experiences. Healthy women volunteers ages 21 to 37 were 
recruited on the basis of the following eligtbility criteria: refrained from taking oral 
contraceptives for at least six months prior to starting the study, experienced regular 
cycles of normal length (21-36 days), and bad previously used tampons. The initial 
meeting between the investigator and participant took about an hour. During that time, 
the participant first learned about the Menstrual Cycle Diary© (Prior, 1990) and an._-.wered 
questions regarding their health.. diet, exercise habits, and history of menstruation and 
reproduction from a subset of the Ba.c;eline Questionnaire for C-aMo.vf;;', the C-anadian 
Mu1ticentre Osteoporosis Study. Each woman signed a consent fonn outlining the 
protocol approved by the Human Investigation Committee, Faculty of Medicine~ 
Memorial University of Newfoundland The participants were given a copy of their 
signed consent form, 3 copies of the Menstrual Cycle Diary© (one for each cycle)~ and an 
explanation sheet describing briefly the meru,"'trual cycle, the study protocol and the 
Menstrual Cycle Diary®. See Appendix A for a copy of the consent form, Menstrual 
Cycle Diary©, and explanation sheet 
As participants. the women agreed to the following: keep a daily Menstrual Cycle 
Diary© for three menstrual cycles; record morning ora1 temperature for a three cycle 
period; monitor vaginal stretchiness of mucus daily for a three cycle period; have finger-
prick blood samples taken; and collect all used tampons during the first two full days of 
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flow for three consecutive menstrual periods (Figure 2). Each woman began the study on 
the first day of her period 
2.2 Temperature Recording 
Each woman was provided with a digital thermometer (Becton Dickinson). Oral 
tempemture was taken in the morning before rising from bed This was required eveJY 
morning for the entire study period. Temperature was recorded in the designated section 
of the Menstrual Cycle Dimy©. Missed days were left blank and the participants were 
asked to make note of illness. poor sleep. and late or early rising. Two types of Becton 
Dickinson digital thermometers were used during the study, one which read to one 
decimal place and the other which read to two decimal places. One of each thermometer 
type was returned UfX>n request by two study participants in order to test the accuracy and 
precision of the thermometers. The thermometers were simultaneously tested twenty 
times at twenty different temperatures. The readings from the two thennometers were 
compared to a calibrated reference thermometer. 
2.3 Menstrual Cycle Diary© 
The Menstrual Cycle Diary® consists of a 21-item list of emotional and physical 
experiences with a column for each day of the cycle and was completed in the evening 
before going to bed (Prior, 1996). The experiences were recorded using either one of two 
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coding systems. The upper section of the diary consisted of experiences that a woman 
may/may not observe on different days of her cycle such as breast tenderness, cramps, 
headache, and depression and were rated for intensity on a 0-4 scale. The lower section 
of the diary consisted of experiences that occur daily but that may fluctuate from its usual 
state which were letter-rated: M (much less), L (a little less), U (usual), Y (a little 
increased), and Z (much increased). These experiences included appetite, breast size, 
feeling of self-worth and outside stresses. At the base of the diary was a designated area 
for temperature recordings and comments such as illness, poor sleep, late/early rise. 
2.4 Monitoring Vaginal Mucus Stretchiness 
Each woman monitored her vaginal mucus stretchiness each day she was not 
observing menstrual flow. An observation of 6-8 em in mucus stretchiness was deemed 
maximal. The women were requested to call the investigator when maximal mucus 
stretchiness was observed To monitor the stretchiness of cervical mucus, a woman 
would insert her index and middle fingers into her vagina, remove them and spread her 
fingers apart observing the abundance and stretchiness of the mucus. Ratings of mucus 
stretchiness were recorded on the Menstrual Cycle Diary© under the heading "Mucus 
Secretions'. A scant or dry mucus observation received a reading of zero; increasing 
abundance and stretchiness of mucus received a rating between one and three and an 
observation of maximal mucus stretchiness (i.e. 6-8 em in stretchiness) a rating of four. 
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Diary 1 Oiary2 Oicuy3 
Daily temperature monitoring 
I ~s:gl 
Figure 2. Timeline of the study protocol 
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2.5 Finger-prick Blood Sampling 
Finger-prick blood sampling took place at the participant's home, her work place 
or at the investigator's laboratory located at the Health Sciences Centre. The tip of the 
finger was first swabbed with alcohol and wiped dry with gauze (patient ready, 2x2). 
Blood was drawn at the tip of the finger using a lancet (Becton Dickinson), a device with 
a retractable blade used to make a small incision. By gently squeezing the finger, eight 
free-flowing drops of blood were collected onto two filter paper cards (Mandel, Blood 
Collection Card #903). Each blood collection card was labeled with the participant's 
code, the date and time of sampling, and the sample number. The blood spots were air-
dried at the laboratory, placed in plastic bags and stored in a -20°C freezer until 
radioimmunoassay (RIA). An additional drop ofblood was collected in a capillary tube 
and capped at one end with a crito-cap (Monoject Scientific, Sherwood Medical) then 
centrifuged (5 min) and hematocrit measured using a Damon!JEC Division micro-
capillary reader. 
No finger-prick blood samples were taken during the first cycle but were taken 
during the second and third cycles. A series of seven finger-prick blood samples were 
obtained during each of the two cycles: three during the follicular phase, three during the 
luteal phase and one on the first day of menstrual flow. The timing of finger-prick blood 
samples relied on the observation of maximal stretchiness of vaginal mucus, a rating of 
four on the Menstrual Cycle Diarye. The participants contacted the investigator once 
maximal stretchiness was observed and a meeting was arranged within 24 hours after 
contact. Finger-prick blood samples were then taken for three consecutive days and 
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again tor another three consecutive days about 5-7 days later. The women were also 
asked to contact the investigator once her period began. Finger-prick blood samples were 
collected within 24 hours of that call. 
2.6 Collection ofUsed Tampons 
The participants were provided with a box of tampons (Kotex ReguJar); screw-
top, opaque plastic bottles for storing the used tampons; two Ziploc plastic bags; a 
permanent black marker; and coded labels. Tampons were generously donated by 
Kimberly-Clark (USA). Used tampons were collected by the participants for the first two 
full days of menstrual flow. Once a used tampon was placed in a bottle .. a label was 
applied and the date and time recorded. The bottles were placed in a plastic bag and 
stored in the participant's freezer until a time for sample exchange was arranged The 
samples were then stored at -20°C in a freezer in the Health Sciences Centre. 
2.7 E:x1:raction ofTampons 
All glassware used in the extraction was silanized with 1% vlv 
dichlorodimethylsilane (Aldrich Chemical Company Inc.) in toluene (HPLC Grade? 
Fisher Scientific), air-dried, then rinsed twice with methanol and air-dried. Before 
silanization, re-used glassware were first washed in detergen~ rinsed with tap water then 
twice with deionized water, baked under high heat for 1-2 hours, cooled. rinsed with 
methanol, andre-baked under high beat for another 1-2 hours. 
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Used tampons were removed from storage and individually weighed. Each 
tampon was submerged in 100 ml methanol (Optim~ Fisher Scientific) in separate 250 
ml Erlenmeyer flasks (Peddle, 1996). Methanol was used to extract progesterone from 
menstrual fluid on the tampon. The flasks were capped with aluminum foiJ, vortexed 
(speed 3 for 5 min, sMf> Multi-Tube Vortexer). stored in a 4°C refrigerator overnight. 
and revortexed again (speed 3 for 5 min) the following day (Peddle, 1996). The tampons 
were squeezed dry and discarded. About 60 ml of the methanol extract was transferred 
into two, 50-ml glass tubes (30 ml each tube) and centrifuged (3000 rpm for 10 min~ 
Sorvall RT6000). About 25 ml of extract from each tube was evaporated under nitrogen 
(N2) and heat (in fume hood, N-Evap Organomations Assoc.) in 5 ml increments into a 
third 50-ml glass tube. TI1ese tubes were capped and refrigerated until the following 
morning. Ether (5 ml, PRA Grade, Aldrich Chemical Company Inc.) was then added to 
each tube to precipitate out possible protein and non-lipid components from the extracts. 
The tubes were vortexed vigorously (Max MinTM Thermolyne Vortexer), and centrifuged 
(3000 rpm for 10 min). From each tube, 4 ml's of extract was evaporated under nitrogen 
(N2) and heat (in fume hood) in I ml increments into 16x 100 glass culture tubes. 
Acetonitrile (3 ml, Optima, Fisher Scientific) .. into which the progesterone dissolvet\ was 
added to the tubes. which were then vortexed vigorously. Hexane (3 ml, Opti~ Fisher 
Scientific) was then added to dissolve lipid components of the extract The tubes were 
revortexed and centrifuged ( 15 min at 3000 rpm). The immiscible layers (hexane on top) 
were then separated :into two 16x 100 culture· tubes. Acetonitrile (2 ml) was added to the 
hexane extract and hexane (2 ml) added to the acetonitrile extract The samples were 
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vortexed and centrifuged (15 min at 300 rpm) and placed in a -200C freezer (30 min). 
Once removed from the freezer, the layers were again separated into two 16xl00 tubes. 
Acetonitrile (2 ml) was added to the hexane extract and hexane (2 ml) to the acetonitrile 
extract. The samples were vortexed, centrifuged ( 15 at 3000 rpm)~ and placed in the 
freezer ( -20°C for 30 min). Afterwar<L the hexane layers were discarded and the 
acteonitrile layers combined and placed in the freezer ( -200C for 30 min). Remaining 
hexane was removed and discarded. The acetonitrile extract was evaporated under 
nitrogen (N2) and beat and stored in a -20'-'C freezer until the radioimmunoassays (RIAs) 
were performed. 
2.8 Validation ofMethodology 
The process of extracting hormone from both the bloodspot filter cards and the 
tampons first had to be validated Below are the steps taken to validate these two 
methods. 
2.8. 1 Finger-prick Bloodspot Assay 
To validate the bloodspot assay of progesterone against the gold standard of a 
serum assay, low, medium and high concentrations of progesterone were needed from 
contemporaneous samples. This range of progesterone was obtained by collecting 
samples from women during the follicular phase, the luteal phase and during pregnancy, 
respectively. One pregnant woman and nine women with regular cycles were recruited 
Each woman signed a consent form outlining the protocol approved by the Human 
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Investigation Committee (See Appendix A). The volunteers gave sequential finger-prick 
blood and serum samples once during the follicuJar phase and once during the luteal 
phase. One tube of serum ( 4 ml) by venous sampling and 4-8 drops ofblood by finger-
prick sampling were coHected each time. The pregnant volunteer only needed to provide 
serum and finger-prick blood samples one time. Venous sampling was performed by a 
trained phlebotomist Serum was centrifuged (20 min~ 3000rpm )~ portioned into stomge 
tubes, and frozen until radioimmunoassays were performed 
Serum and finger-prick blood samples were measured in duplicate using a 
commercially available radioimmunoassay kit (DSL-3900~ Pro-lab Diagnostics). 
Standards and controls for the finger -prick blood sample assay were prepared by 
pipetting several 25 J.d drops of each standard and control from the kit onto ldter cards. 
The filter cards were air-dried and stored at -20°C. Twelve 118& inch diameter discs of 
standards, controls, and unknowns were punched from the filter cards and added to the 
assay tubes. 
The efficacy of recovery of hormone was determined by spiking a sample of 
.known low progesterone (foHicuJar phase finger-prick blood sample) with elevated 
amounts of progesterone prepared on filter cards using progesterone standards from the 
RIA kit To the assay tubes were added twelve l/8th inch diameter discs: eight discs of 
the follicular phase sample and four discs of standard A (0 nglml) for the controt 
standard D (4.5 nglml), standard E (20 nglml), or standard F (70 ng/ml). Assuming that 
25 J.!L of progesterone standard fills the entire 1.19 cm2 circle on the fihercards. the 
expected progesterone concentrations were calculated for progesterone standards D (4 .5 
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ng/ml), E (20 ng/ml), and F (70 ngfml). As it takes 15 times the amount of progesterone 
in one 1/8th disc to be equivalent to the amount of one fuJJ circle, the expected 
progesterone concentrations in the four l/8th discs added to the follicular phase sample for 
standards D, E, and F are J .2 ng/ml, 5.3 ng!ml, and 18.7 nglml. respectively. 
Linearity was determined by diluting a finger-prick blood sample of known high 
progesterone concentration (pregnancy sample) with a finger-prick blood sample of 
known low progesterone concentration (menopausal sample) by a factor of a half (1fl)~ a 
quarter (1/4 ), and an eighth ( l/8). To the assay tubes, for the half dilution, were added 
six discs of the pregnancy sample and six discs of the menopausal sample; for the quarter 
dilution, three discs of the pregnancy sample and nine discs of the menopausal sample; 
and for the eighth dilution, 1.5 discs ofthe pregnancy sample and 10.5 discs of the 
menopausal sample. 
Intra-assay precision of the finger-prick blood assay was determined by the mean 
of ten replicates of a low progesterone sample (follicular phase sample). Inter -assay 
variability was determined by assaying (in duplicate) the same sample on eight different 
occasions. 
2.8.2 Validation ofExtraction Method 
The efficacy of the extraction of progesterone from used sanitaly products was 
validated two ways: 
In the first validation procedure un-used tampons were removed :from the 
applicator and doped with 1 ml of 8 ng/ml, 16 ng/ml. 32 ng/ml, 64 ngfml, or 128 ngfml 
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progesterone in ethanol The tampons were stored in labeled. opaque~ plastic bottl~ and 
stored in a ~20°C fteezer until extracted 
The second validation procedure involved extracting progesterone of known 
amount :from tampons that mimicked actuaJ used tampons during menstruaJ flow. To 
simulate used tampons. un-used tampons were doused with progesterone-doped 
menstrual fluid A correspondent :from the University of British CoJwnbia was recruited 
to collect menstrual flow for one full period Recruitment fell under the same guidelines 
as in the original study. Menstrual fluid was collected with The Keeper,. a rubber 
receptacle for menstrual fluid The volunteer was a current user of The Keeper. 
Collected menstruaJ flow was emptied into several steriJe plastic containers and stored at 
freezer temperature until shipped (under dry ice) to Newfoundland The containers were 
then stored at -200C. In preparation for extraction, the samples were thawed and pooled 
Phosphate buffered saline (15 ml) was added to thin the fluid,. which was then divided 
into four equal portions ( -11 ml). Each portion received 220 J1] ethanol alone, 200 nghnJ, 
600 ngfml, or 1200 ngfml progesterone in ethanol to yield a final concentration of at least 
0 ng/ml,. 4 ng/ml,. 12 ng/mJ,. and 24 ng/mJ, respectively. To maintain the integrity of the 
menstrual fluid,. the addition of ethanol alone or progesterone in ethanol equaled only ?-At 
of the to1al volume. Un-used tampons were removed from the applicator and doped with 
5 ml of menstrual fluid The tampons were placed in labeled. opaque~ plastic bottles and 
stored at -20°C until exttacted.. 
Samples were measured in duplicate using a radioimmunoassay tit (DSL 3900, 
Pro-Jab Diagnostics). Before assay,. the samples were reconstituted with 1 mJ Standard A 
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buffer (0 nglml, DSL 3900-100, Pro-lab Diagnostics), vortexed vigorously and sonicated 
for 30 min (Bransonic 3510 ultrasonic cleaner) and then gently vortexed immediately 
before addition to the assay tube. Hexane extracts were also retained and assayed tor the 
validation. 
Linearity of the assay was determined by diluting a high progesterone sample (un-
used tampon doped with 5 ml of24 ng/ml Pin menstrual fluid) with progesterone 
Standard A (0 nglml) by a dilution factor of a half (112), a quarter (1/4), and an eighth 
(1/8). 
Intra-assay precision was determined from the mean of ten replicates of a low 
(un-used tampon doped with 5 mJ of 4 ng/ml P in menstrual fluid), medium (un-used 
tampon doped with 5 ml of 12 nglml P in menstrual fluid), or high progesterone sample 
(un-used tampon doped with 5 ml of24 ng/ml Pin menstrual fluid). Inter-assay 
variability was determined by assaying (in duplicate) a high progesterone sample (un-
used tampon doped with 5 ml of24 nglml P in menstrual fluid) on four different 
occastons. 
2.9 Gas Chromatography-Mass Spectrometry (GC-MS) 
Initial extractions of blank un-used tampons showed a measurable amount of 
progesterone in the RIA print-out. Several un-used tampons were extracted, reconstituted 
with 500 J..ll methanol. and analyzed for progesterone using gas chromatography-mass 
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spectrometry (GC-MS). Taking into consideration the sensitivity of the procedure a 
sample concentrated I OX was also analyzed for progesterone. 
2.10 Determination of Menstrual Cycle Characteristics 
Progesterone measured from the bloodspots was used as the gold standard when 
determining menstrual function. Luteal phase lengths were considered short if they were 
less then 12 days in length from the onset of progesterone greater than 5 ngfml or from 
the time of maximal mucus observation. Cycles having normal progesterone secretion 
(bloodspot progesterone > 5 nglml and mid-luteal peak~ 14 ngfml) with adequate cycle 
and luteal phase lengths (21-36, ~ 12 days, respectively) were considered to have normal 
luteal function and likely ovulatory. Cycles were considered not to have a functional CL 
and were likely anovulatory (non-functional CL) when progesterone values were Jess 
than 5 uglml. Progesterone concentrations were charted against cycle day. Three experts 
in the field of reproductive endocrinology used the graphs to detennine the nonnalcy of 
each cycle. The cycle was so categorized when 2 of3 experts were in agreement 
2.11 Statistical Analysis 
Regression analysis was used to assess the validity of the bloodspot assay and 
extraction method Temperature data from each cycle were analyzed using the 
Maximina® Quantitative Basal Temperature Analysis Program (See section 1.6.2 for 
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further explanation). The Maximina ® results were then analyzed by three independent 
experts. The cycles were categorized as 'ovulatory' or 'anovulatory' when 2 of3 experts 
were in agreement Specificity, sensitivity, and the predictive ability of the finger -prick 
blood sampling and temperature method in detennining CL function were assessed using 
computations from Sackett et al. (2000). 
A repeated measures analysis of variance was used to detennine effect of sample 
number of the extracted tampons (i.e. sample number l, 3, 5, 7). That is, whether there is 
a significant difference in progesterone concentrations meastued from any of the four 
extracted tampons. AU other statistical comparisons were done using nonparametric 
tests. The Kruskal-Wallis test was used to detennine a difference in ext:mcted samples 
from cycles with varying degrees of functional CL (i.e. Ovulatory/Normal vs. SLP vs. 
Insufficient). Otherwise, the Mann-Whitney U test was used for all other extracted 
sample comparisons. SPSS for Windows (Version 11.5) was used for these analyses and 
values ofp < 0.05 were considered significant. 
The purpose of the Menstrual Cycle Diary® in this study is to determine whether 
physical and emotional experiences obseiVed during the menstrual cycJe differ for 
ovulatory and anovulatory cycles. Varying menstrual cycle lengths among the 
participants makes it difficult to analyze scores from the dai1y Menstrual Cycle Diary e. 
To maximize the data for cycles with corresponding bloodspot data, scores were 
examined within one 5-day mid-cycle window (MC, 11-15) and one 5-day end of cycle 
window (EC, last 5 days of the cycle). These days were chosen to assess physical and 
emotional changes during the follicular and luteal phases. Each participant experienced 
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at least three days of menses, therefore, a 3-day menstrual window was examined. The 
first few days of a menstrual cycle could be influenced by ovulatory function of the 
previous cycle; therefore, scores from the 3-day window were taken from the proceeding 
cycle (3D A, first 3 days of onset of the following cycle). Scores for each oftbe three 
windows were summed and averaged to account for missing data. For the analysis,. the 
letter scores were given numerical values (M = 0, L = 1, U = 2, Y = 3, Z = 4). Depending 
on the experience analyzed it is possible that scores from some days of the menstrual 
cycle are less informative than other days. Single factor analysis of variance (ANOVA) 
was used (Microsoft Excel 10.2) to determine cyclicity among the scores from the three 
windows. For those experiences with a significant cyclic pattern, scores from a particular 
window were not included in subsequent analyses if the average score was close to the 
'usual' score ("O"for those diary items with number-scores or '"2" for diary items with 
letter-scores). Otherwise, scores from all three windows were used. The Mann-Whitney 
U test (SPSS for Windows 1 1.5) was used to assess whether experiences differed 
between cycles with and without a functional CL (i.e. ovulatory vs. anovulatory). Alpha 
was set at 0.05 and only significant results are reported 
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3.0 Results 
3.1 Menstrual Cycle Characteristics of the Study Participants 
A total of 52 completed menstruaJ cycle records were coJiected from J 8 women 
giving an average of2.9 cycles per participant Table 2 shows the menstrual cycle 
characteristics of the study participants. The average cycle length was 29.3 ± 6.7 days 
with a range 21-72 days. Two participants had oligomenorrheic cycles during the study 
period (cycle lengths: 39 and 72). Out of 52 cycles, 33 had correspon~ng finger-prick 
bloodspot data. Among the 18 women, 16% (3 of 18) showed no evidence ofCL 
function and were termed "anovulatory'". The remaining women showed varying degrees 
of CL function, sufficient that they were deemed "ovulatory". However, of those with 
"ovulatory'' cycles, only in 53% (8 of 1 5) did they appear normal. One or more short 
luteal phase lengths were observed in 66% (1 0 of 15) of the women and 26% (4 of 15) of 
the women had at least one insufficient luteal phase. 
Twenty-eight women were initially recruited for the study but onJy eighteen 
women provided at least two full cycles worth of data Reasons for withdrawing from the 
study were pregnancy (one woman). starting birth control (three), discomfort with aspects 
of the study protocol (two), an occupational move (one), or personal reasons (three). 
3.2 Validation- Finger-prick Bloodspot 
3.2.1 Serum vs. Finger-prickBloodspot 
Contemporaneous serum and bloodspot samples were assayed for progesterone. 
Regression analysis gave the relationship of y (serum)= 0.4338x + 0.4328 (R2 = 0.9963, 
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n = 10) allowing for the conversion ofbloodspot samples to serum equivalents (Figure 3). 
Figure 4 shows the profiles of the ten contemporaneous serum and finger-prick blood 
progesterone concentrations. 
3.2.2 Recovery 
Converting the progesterone standards (serum) expected values to bloodspot 
values using the regression equation y (bloodspot) = 2.2965x- 0.925, the expected 
progesterone concentrations in the four l/8th discs added to the follicular phase sample 
for standards D, E, and F are 1.83 ng/ml, 11.32 ng/ml, and 41.94 ng/ml, respectively. 
Observed results were adjusted subtracting the baseline RIA progesterone concentration 
2. 73 ng/ml (follicular phase sample+ Standard A (0 ng/ml)). Regression analysis of the 
observed and expected progesterone recovery provided a squared correlation coefficient 
R2 = 0.9997 (n = 3). Figure 5 shows the correlation between expected progesterone 
recovery and observed recovery of progesterone concentrations. 
3.2.3 Linearity 
Dilution ( l/2, l/4, l/8) of a pregnancy bloodspot sample (high progesterone) with 
a menopausal bloodspot sample (low progesterone), reported as a linear regression 
between expected and observed progesterone concentrations was ~ = 0.9519 (n = 3). 
Figure 6 shows the correlation between expected and observed dilution results. 
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Table 2. Menstrual cycle characteristics based on finger-prick blood progesrerone analysis and 
mucus determinations of 18 premenopausal women during the study period 
--· ---~-,-------
----------·----
Cycle length (days) 
Range (days) 
Menstrual cycle analysis 
293±6.7 
21-n 
Normal cycleS 8 
Short luteal phases (SLP) 
1 8 
>1 2 
Insufficient luteal phases (ILP) 4 
Anovulatoty cycles 3 
Cycle Jength (days) 
>36days 
<21 days 
2 
0 
* Some women had both SLP and ILP tlrus were counted in more then one category 
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y = 0.4338x + 0.4328 
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Figure 3. Correlation between serum and finger-prick bloodspot progesterone 
concentrations 
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Figure 4. Profiles of contemporaneous serum and finger-prick progesterone concentrations from 
six women during the follicular phase (• ). luteal phase (+ ). or first trimester of pregnancy (A.) 
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E'lJOCled P oonc. (ndmJ) 
Figure 5. Correlation between expected and observed recovery of added progesterone (P) fiom 
finger-prick blood samples 
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3.2.4 Assay Variability 
The intra-assay %CV based on 10 determinations from a single finger-prick 
blood sample was 9.66. The inter-assay %CV based on eight detenninations measured in 
duplicate from the same sample was 23.04. 
3.3 Hematocrit 
Hematocrit was measured using tbe microcapillary method. The population mean 
(± SD) hematocrit measurement was 33.7 ± 3.22. Thus~ for every 100 J!L, there is about 
66.3 J.lL of serum. Table 3 shows a selection of extreme hematocrit values and the 
adjustment of the corresponding finger-prick blood raw progesterone concentrations 
based on hematocrit values and intra- and inter-assay variability. The adjustment of 
progesterone concentrations for hematocrit was based on the percentage difference 
between an individual serum value (converted from the hematocrit value) and the 
population mean serum value (i.e. 66.3). For example, a hematocrit value of26.9 wuuld 
have a serum value 73.1 which is 9.3% more then the population mean serum value. The 
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Figure 6. Correlation between expected and observed results of the dilution (l/2, l/4, l/8) of a 
high progesterone (P} tmger-prick blood sample with a low progesterone tmger-prick blood 
sample 
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corresponding progesterone value would be adjusted for that difference. The adjusted 
progesterone values from Table 3 show that the hematocrit contributed uncertainty 
similar to that ofbloodspot intra-assay %CV. That is, when taking into account 
hematocrit and intrn-assay variability~ the adjustment of progesterone was similar for 
both. Inter -assay o/oCV contnbuted uncertainty of a slightly greater magnitude than that 
of hematocrit That is, the change in progesterone concentration was greater for inter-
assay variability than for hematocrit TI1erefore, it was not necessary to adjust the 
progesterone concentrations on the basis of the hematocrit values. 
3.4 Gas Chromatography-Mass Spectrometiy (GC-MS) 
Assays of extracts from blank un-used tampons showed measurable progestemne 
concentmtions. The mean (± SD) progesterone concentmtion for 10 un-used tampons 
was 1.203 ng/ml ± 0.245. Extractions of un-used tampons including a sample 
concentrated 1 OX were measured for progesterone using GC-MS. The GC-~MS resuJts 
showed no indication of actual progesterone in either the acetonitrile or hexane extracts. 
The concentrated sample (I OX) also showed no progesterone. Appendix B sho\vs the 
results for the lOX samples (both acetonitrile and hexane extracts) only. 
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l 
Table 3. From finger-prick blood samples, the comparison of the adjustment of raw progesterone 
(P) based on extreme hematocrit values. intra- and inter-assay variability 
I Ad,justed P (nglml) based on: 
I I Intra:-assay I Inter-assay Hematocrit A difference RawP Hematocrit 9.66%CV 23_04,.0CV % %* (ngfml) range ~ range 
26.9 -9.3 2.6 2.4 ' 2.4-2.9 
~ 
2.0-3.3 
26.9 -9.3 12.5 11.4 11.3-13.7 I 9.6-15.4 
40.9 +12.1 1.7 1.9 1.5-1.9 1.3-2.1 
27.4 -8.7 5.0 4.6 4.6-5.5 I 3.9-6.2 I 
42.1 +14.5 14.4 16.4 13.0-15.8 JJ.J-17.7 
43.2 +16.7 2.8 3.2 2.5-3.0 2.1-3.4 
*Population mean hematocrit was 33.7. Thus,. for every 100 p1 there were 66.3 pl of :serum. The A 
difference% was calculated by converting individual hematocrit values to serum values (e.g. 26.9 = 73.1) 
then determining its percentage difference from the population serum value (i.e. 66.3). 
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3.5 Validation- Extraction Method 
Both the acetonitrile and hexane extracts were assayed during the validation 
process. As anticipated the acetonitrile layer contained the bulk of the expected 
progesterone concentration while the hexane layer contained a negligible amount of 
hormone. Thus and thereafter the hexane layer was discarded at the final step of the 
extraction procedure. 
Un-used tampons were doped with 1 ml of8 nglml, 16 nglml, 32 nglml, 64 nglml, 
or 128 ng/ml of progesterone in ethanol. The validity of the extraction method was 
measured through recovery and dilution of progesterone in the samples. 11le expected 
recovery of progesterone was calculated taking into account only half of the initial 100 
ml methanol extract was further extracted and the 20% loss of extract during the ether 
purification step. Regression analysis gave a high squared correlation coefficient for 
recovery and dilution (R2 = 0.9887, R2 = 0.9767. respectively). The intra,..assay 
variability based on lO determinations of3 samples doped with l ml of 16 nglml, 32 
nglml, or 128 nglml progesterone in ethanol averaged 14.07 (range 5.5- 19.03). 
Repetition of this validation procedure gave similar results. As a resul~ continuation 
with the second validation procedure ensued 
3.5.1 Recovery 
Un-used tampons were doped with 5 ml of 0 nglml, 4 nglml, 12 nglml. or 24 
nglml of progesterone in menstrual flow resulting in the expected progesterone 
concentration 0 nglml, 20 nglml, 60 nglml, or 120 nglml per tampon. Six tampon 
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samples were extracted for this validation, two tor each progesterone concentration 
above. The RIA results of two samples (0 ng/ml and 20 nglml) were not included in the 
overall analysis due to pipetting errors during the doping process. ln addition to taking 
into account procedural extraction losses (explained above) the baseline value ( 1 .8752 
ng/ml) measured from an un-used tampon doped with 5 ml of menstrual tlow without 
added progesterone (i.e. the 0 nglml sample) was calculated into the expected recovery 
results. The values obtained for expected and observed recovery of added progesterone 
were highly correlated in a linear regression (R2 = 0.991, regression equation y = 0.9319x 
+ 0.826, n = 4, Figure 7). 
3.5.2 Linearity 
The dilution (1/2, 114, 1/8) of an un-used tampon doped with 120 ngfml 
progesterone (in menstrual fluid) with Standard A buffer (0 ng/ml) reported as a linear 
regression between expected and observed results was R2 = 0.9969 (y = 1.1 088x -
6.3604, n = 3). Figure 8 shows the correlation between the expected and obseJVed result~ 
from the dllution of the extracted sample. 
3.5.3 Assay Variabllity 
Intra-assay %CV based on lO determinations of 4 samples (0 nglml. 20 nglml. 60 
ng/ml. 120 ng/ml) averaged 6.25 with a range 4.12- 8.16. The inter-assay o/oC'V based 
on 4 determinations of a single sample ( 120 nglml progesterone-doped sample) measured 
in duplicate was 13 .36. 
65 
60' 
~50 
~ 40 g 
& 30 ll.. 
] 20 
~ 
<3 10 
• 
0+-------~-----~~----~------~------~----~, 
0 lO 20 30 40 50 60 
Expected P oonc. (ngfml) 
Figure 7. Correlation between expected and observed recovety of extracted progesterone (P) from 
un-used tampons doped with increasing concentrations of progesterone-doped menstrua) fluid 
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Figure 8. Correlation between expected and observed dilution (112. 1/4, 118) of an extracted 
sample doped with 120 nglml of progesterone (P) in menstrual fluid and diluted with Standard A 
(Ong/m1) 
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3.6 Corpus Luteum (CL) Functioning 
3.6. 1 Finger-prick B1oodspot 
Finger-prick blood samples were requested from each subject at seven different 
occasions during her menstrual cycle. Seven bloodspot samples could not be coHected 
for every participant but each woman gave at least two fmger-prick blood samples per 
cycle. The finger-prick blood samples were assayed for progesterone and those 
bloodspot values converted to serum values ( nglml) using the regression equation y 
(serum)= 0.4338x + 0.4328. Progesterone concentrations were charted 3.!,.'3inst cycle day 
(Figure 9). 
Using progesterone concentration as the gold standard, 33 cycles were grouped 
into one of two categories: functional CL and non-functional CL. Out of those 33 cycles, 
28 cycles (85%) were detennined to have a functional CL and 5 ( 15%) showed no signs 
ofCL functioning. Out of those cycles determined to have a functional CL, 12 of28 
(43%) had adequate cycle and luteal phase lengths (21-36 days, ~12 days. respectively); 
12 of28 (43%) were categorized as having SLP (~ 11 days); and 4 cycles (14%) 
categorized as ILP (P < 14 ngfmJ) but having adequate luteal phase len1,Jths (Table 4). 
3.6.2 Temperature 
Basal body temperature was recorded daily by each of the participants (Figure 9). 
The temperature data were analyzed using the Maximina ® Quantitative Basal Body 
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Temperature Analysis Program and also using the analysis of the three experts. The 
cycles were categorized when 2 of 3 experts were in agreement Disagreement with 
Maximina ® occurred only twice in which the experts overruled the program's analysis 
categorizing two cycles as non-functional (graph AH, cycle 2; graph AC, cycle 2; Figure 
9). According to the final analysis, 24 cycles were ovulatory (i.e. bad a functional U.) 
and 9 cycles failed to show a persistent rise in temperature thus were categorized as 
anovulatory (Table 4). 
3. 7 Comparison of Finger-prick Bloodspot and Temperature Analysis 
Using finger-prick blood progesterone as the gold standard, agreement between 
the analyses from bloodspot sampling method and temperature method was assessed 
(Table 5). The specificity was found to be 82.1% while sensitivity was 80%. That is, 
when using both methods of analysis anovulatory cycles were correctly identified 82.1% 
of the time while ovulatory cycles were identified 80.0% of the time. When bloodspot 
analysis predicted ovulation, there was a 95.8% chance that the temperature analysis 
would also predict an ovulatory cycle. However, when the bloodspot analysis predicted 
a non-functioning CL (i.e. anovulation), temperature analysis would predict the same 
only 44.4% of the time. 
Two types of Becton Dickinson digital thermometers were used during the study, 
one which read to one decimal place and the other which read to two decimal places. 
Newly purchased thermometers were available reading to the one decimal place only. 
The mean difference of the two digit thermometer from the reference thermometer was 
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Table 4. Menstrual cycle characteristics ofthirty-lhree menstrual cycles based on finger-prick 
bloodspot and temperature analysis 
Bloodspot QBT 
no. ofcycle.Y: 
Menstrual cycle analysis 
Ovulatory cycles 28 24 
Normal cycles 12 19' 
Short luteal phases 12 5 
Insufficient luteal phases 4 NA 
Anovulatory cycles 5 9 
QBT, Quantitative basal temperature; NA, not applicable 
15 
Table 5. Sensitivity, specificity, positive and negative predictive value of the finger-prick blood 
analysis of corpus luteum (CL) function of33 cycles in comparison to the temperature analysis 
Finger-prick Blood Analysis 
FunctionaJCL Non-functional CL 
Ne.ofqeles 
.Ne.ofc::rdes 
Temperature Functional CL 23 1 Analysis No. of cycles 
Non-functional CL 5 4 
Ne. of cycles 
Sensitivity 80.()0;;, Positive Predictive I 95.8% Value 
Specificity 82.1% Negative Predictive 44.4% 
Value 
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0.30 (range 0.18-0.44) and for the one digit thermometer, the mean difference was 0.25 
(range 0.1-0.4). Regression analysis demonstrated that both thennometers were 
consistently reading about a 0.20°C higher than the reference thermometer at each test 
temperature (y = 1.0134x + 0.2335~ for two digit readout; y = 1.01 l3x + 0.1952, for one 
digit readout). 
3.8 Extraction Results 
A total of 110 used tampons were collected and extracted. Samples 1, 3. 5. and 7 
were extracted for each cycle. Tampons from 32 menstrual cycles were measured for 
progesterone (used tampons from one of the 33 cycles with corresponding bloodspot data 
were not collected). Each participant coiJected and stored at least three 1ampons per 
cycle. Two values were clearly outliers and omitted from statistical analysis (33.35 
ng/ml, 134.27 ng/ml). Progesterone values obtained from the assay print-out were 
adjusted to take into account the weight of the sample and procedural extraction losses. 
The weight of each tampon was subtracted by the average weight from ten un-used 
tampons to give us the weight of menstrual effluent. as .. ~ming 1 ml for each gram. The 
mean adjusted progesterone value (± SD) was 1.98 nglg ± 0.85 (range 0.28 nglg- 7. 85 
nglg). The adjusted progesterone values were used for statistical analyses (Table 6). 
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Table 6. AdWII and mean (M) raw ud adjusted extracted progesterone coooentnotions (oglml) 
from used lam pons (I, 3, 5, and 7) of32 menstrual periods. 
~l!liii!II<CL»- I '• f!lillllll IIIII ., Alii IIUWI)• . ~ I 3 3 7 I 3 s 7 M 
1.9 2.42 us 2.32 l.tS 2.94 1.94 0.91 1.93 
1.91 3.74 1.78 1.91 2.33 7.85 3.31 0.88 1.11 
2.29 4.53 2.37 2.04 :UI 5.05 6.23 1.08 0.64 
3.46 2.19 1.57 1.93 2.29 3.29 3.51 3.07 1.37 
Nonnal 2.59 0.15 2.74 1.86 2.11 1.24 2.29 1.42 1.01 
1.98 1.70 2.33 2.110 3.99 0.55 1.19 
1.60 2.57 l.OO 1.91 2.27 1.23 1.23 1.17 3.28 
1.99 2.09 2.52 2.57 2.29 1.45 2.27 2.46 3.31 
2.72 2.62 2.53 U2 0.82 1.00 0.90 
6.02 2.50 2.25 :u' us 0.62 0.79 
1.47 3.)4 U4 1.06 1.75 4.29 4.11 2.76 4 .30 
FuncllOOal CL 2.89 4.71 3.06 3..'15 1.48 4.14 2.62 
(ovul~ cycles) 2.3) 1.11 2.32 2.15 6.56 2.13 2.20 
1.87 2.31 2.66 1.91 2.11 2.08 1.18 1.11 1.15 
1.51 1.61 1.!16 1.69 2.25 
6.38 3.13 1.80 2.55 3.A7 1.20 o.n 0.21 0.88 
SLP 5.64 2.60 1.51 3.25 2.21 1.21 1.12 1.79 2.34 2.56 2.22 2.22 1.09 0.66 1.17 2.22 
2.05 1.96 2.75 2.82 2.19 1.11 4.42 2.62 1.27 
1.33 1.17 1.84 2.65 1.75 2.04 1.00 1.87 0.79 
1.96 1.24 IM 1.76 1.10 
1.40 2.71 1.14 L73 1.31 1.08 1.13 
3.49 2.20 3.92 3.2t 1.79 1.44 3.15 
0.93 118 2.12 !AI 2.65 2.31 1.07 
lLP 3.11 2.30 1.62 2.34 1.59 276 0.92 
1.57 108 231 1.46 l.&t 1.31 0.41 3.36 4.94 
0.86 1.711 2.46 1.78 0.73 1.66 0.83 
2.50 3.76 3.13 2.13 1.79 
Non-functional CL 2.18 2.85 2.66 3.74 lM 2.65 2.83 3.00 3.20 
(ODOvulato.y cycles) 1.27 1.19 1.23 1.57 2.27 
3.91 2.08 2.35 2.31 1M 1.57 0.73 0.64 0.94 
1.41 1.91 1.07 I.A6 0.51 0.71 1.81 
. SLP, Shoo luteal plwe.ILP, Insuffietenl ..... phase 
•Blank spaces are missing data from U9CCI tampon samples oot c:oUec:tcd by pwticipt,rQ. 
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3.8.1 Comparison ofExtraction and Bloodspot 
A repeated measures within-subjects test found no significant effect of sample 
number (F = 1.147, p = 0.340). That is, there was no significant difference in 
progesterone within samples 1, 3, 5, and 7. The progesterone vaJues for those samples 
were combined and averaged for further analysis. 
No statistically significant difference was found between the JeveJ of progesterone 
extracted from tampons of ovulatory cycles and anovulatory cycles (U = 57.00. p = 
0.586). Comparing extracts from anovulatory cycles to extracts of ovulatory cycles of 
normal cycle and luteal lengths also showed no statistical significance (U = 23.00, p = 
0.461). 
A three-way comparison of progesterone values from ovulatory cycles of nonnal 
length with cycles of short luteal phases and insufficient luteal phases showed no 
statistical significant difference in progesterone concentration, (p = 0.429~ df= 2). 
As well, there was no significant difference in progesterone extracted from 
samples of normal cycles and cycles with ILP (U = 1 9.00, p = 0.544) nor in cycles with 
SLP when compared to ovulatoty cycles of normal length (U = 45.00, p = 0.196). 
There was also no statistical difference in extracted progesterone concentrations 
from cycles with SLP and ILP cycles (U = 20.00, p = 0.794). 
3.9 Menstrual Cycle Diary© Data 
As a result of the ANOVA, scores from the MC window were not used in further 
analysis for the following menstrual experiences: cramps. front and side breast 
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tenderness, breast size, fluid retention, feeling of energy. and interest in sex. Scores from 
the EC window were not used in further analysis for the foUowing menstrual experiences: 
cramps, mucous secretions and interest in sex. Scores from the 3DA window were not 
used in further analyses in the foUowing menstrual experience: mucus secretions. For all 
other menstrual experiences listed on the Menstrual Cycle Diary©, scores from the 3 
windows (MC, EC, and 3D A) were used in the analysis. 
The Mann-Whitney U test found a significant difference in scores of seven of 
seventeen experiences between cycles with or without a functional CL (Figure 1 0). 
Ovulatory cycles had significantly higher scores for side breast tenderness (U = 15.5, p = 
0.020), cramps (U = 17.0, p = 0.035), fluid retention (U = 8.0, p = 0.006), frustration (U = 
23.0, p = 0.017), sleep problems (U = 15.0, p = 0.006), depression (U = 27.5, p = 0.029). 
and breast size (U = 18.0, p = 0.028). Comparisons between ovulatory and anovulatory 
cycle scores of the ten other menstrual experiences from the Menstrual Cycle Diary® 
were not significant (p > 0.05, data not shown). 
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Figure 10. Representation of seven menstrua] cycle experiences from 1be Daily Menstrual Cycle 
Diar.y@ comparing the mean scores from ovulatory and anovulatory cycles in 18 women. [FuJI 
figure legend on page 83] 
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Figure l 0. Representation of seven menstrual cycle experiences :from the Daily Menstrual Cycle 
Diary0 comparing the mean scores .from ovulatmy and anovulatmy cycles in J 8 women. [FuU 
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Figure 10. Representation of seven menstrual cycle experiences fi:om the Daily Mens1Inal Cycle 
Dial:ye comparing the mean scores fiom ovulatocy and anovulatory cycles in 18 women.. Scores 
were examined within two 5-day windows and one 3-day window for all cyc1es with 
corresponding bloodspot data. Analysis of variance (ANOVA) was used to detennine cyclicity 
among the scores ftwn the three windows. For those experiences with a significant cyclic 
pattern,. scores from mid-cycle (MC), end of cycle (EC). or the first 3 days of the following cycle 
(3D A) were not included in subsequent analyses if the average score was dose to 1he ~usual~ 
score ('0' for number-scored experiences or '2~ for letter-scored experiences). See parenthesis 
below for windows included in analysis for each experience. The Mann-Whitney U test was 1ben 
used to compare scores ftom ovulatoty and anovulatoty cycles. Side breast teodemess (EC. 
3D A), cramps (3D A)~ fluid retention (EC. 3D A). sleep problems (MC. EC, 3D A). feeling 
ftust:rated (MC, EC, 3DA1 and feeling depressed (MC, EC, 3DA) were scored on a 0-4 intensity 
scale; breast size (EC. 3D A) was scored on a letter scale (M =much less. L =a little tess. U = 
usual, Y =a little increased, Z =much increased), which was changed to nmnerical form for 
analysis (M = 0, L = l, U = 2, Y = 3, Z = 4). Scores for o\'Uiatory cycles were statistically higher 
than anovulatocy cycle scores (u = 0.05). 
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4.0 Discussion 
4.1 Tampon Extraction Results and Method Validation 
The purpose of this paper was to validate a novel non-invasive method of 
detennining luteal function in women. This method of measuring progesterone from 
menstrual fluid collected on tampons failed to distinguish menstrual cycles with a 
functional CL from cycles with a non-functional CL. The overall mean adjusted 
progesterone concentration was quite low measuringjust below 2 ngfml(1.98 ± 0.85 
nglml). PeddJe (1996) also measured low progesterone conteirt in menstrual fluid (<2 
ngltampon). Bieglmayer et al. (1995) measured progesterone in used tampons co1lected 
on days 1-3 of menses which averaged 4 ± 1 ng/g (median of2 nglg). Zhou et al. (1989) 
reported low progesterone levels (average of 1.6- 2.6 nmol!L) in menstrual fluid 
collected in rubber receptacles and concluded that menstrual progesterone probably arose 
entirely from peripheral circulation. Neither Peddle ( 1996), Bieglmayer et al. (1995t nor 
Zhou et al. ( 1989) assessed the ovarian status of their participants. 
Progesterone receptors are located in the endometrium (Haukkamaa & 
Luukkainen. 1974; Rao et al., 1974; Janne et al., 1975; Flickinger et al., 1977) which is 
shed during menses. The regulation of estrogen and progesterone receptor expression in 
the endometrium is menstrual cycle-dependent. Estrogen, predominant during the 
follicular phase, stimulates progesterone receptor synthesis in the endometrium whereas 
progesterone, predominant during the luteal phase, likely contnoutes to the degradation 
of its own receptor (Janne eta/., 1975). The regulation of receptor content by steroid 
hormones is evident by the finding that progesterone receptor expression increases during 
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the follicular phase and decreases to low levels during the luteal phase (Punyadeem et al., 
2003). As serum levels of progesterone also decrease towards late luteal phase~ the low 
levels of progesterone in menstrual fluid reported in the present study are not surprising. 
Despite the expected low progesterone concentrations it was hypothesized that 
progesterone concentmtions would be higher in menstrual fluid of ovulatory versus 
anovulatory cycles, however, this study failed to support this hypothesis. In the present 
study, samples 1, 3, 5, and 7 were extracted from the first two days of menses. If the 
source of menstrual fluid progesterone is the blood, then it is unJikely that tampons 
extracted from day 3 onward would have significant progesterone concentrations as the 
majority of menstrual tissue is normally discarded within the first t\vo days of menses 
(Vasilenko eta/., 1988). 
In this study, extracts from used tampons of twenty-seven functional cycles were 
compared to extracts from tampons of only five non-functional cycles. The srnaH sample 
size of five anovulatory cycles presents the possibility of creating a type II error; that is. 
finding no difference in progesterone levels in used tampons between functional and non-
functional cycles when a difference actua1ly exists. This would lower the power of the 
experiment Thus, comparisons with a larger number of extracts from anovulatory cycles 
(as well as extracts from functional cycles) may be necessary to uncover a difference in 
menstrual fluid progesterone between ovulatozy and anovulatory cycles. 
Although progesterone from menstrual fluid was not presented in the present 
study as an appropriate marker for the determination of luteal function, the method of 
extracting progesterone from menstrual fluid colJected on tampons was validated. The 
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regression analysis shows a high correlation between expected and observed progesterone 
concentrations from both the recovery and dilution experiments with satisfactory intra-
and inter-assay variability. The results from the validation experiments show that this 
method of extraction can be used to measure progesterone in menstrual fluid collected on 
tampons. 
Extracted blank tampons gave measurable but false assay readings. The extracted 
blank extracts contain uncharacterized compounds that appear to internet with or bind to 
the antibodies coating the tube giving false progesterone readings. As tbe extraction 
method was validated it does not appear that this affect is additive, however, the 
possibility that these compounds are interfering with the assay cannot be dismissed. 
Hofer et al. (1993) also observed a variety of unknown compounds extracted from blank 
tampons. They suggested that these compounds may be derived from fatty acids bound 
to the tampon material. Blank tampon extracts showed peaks at 237 and 280nm and the 
area of these peaks decreased with the increase in blood volume (Hofer et aL, 1993). 
They too were unable to remove these possible interferences. 
4.2 Bloodspot Validation 
Finger-prick blood sampling was a method used in the present study as an 
alternative to venous sampling. This method provided a minimally invasive, quick, and 
convenient way of collecting blood samples outside the laboratory. Another positive 
result from the present study was the validation of the finger-prick blood assay. In 
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agreement with results from Petsos et al. (1985, 1986), McLoughlin et al. (1994), and 
Shirtcliff et a/. (200 1) the correlation of capiiJary blood and senun progesterone was very 
high using regression analysis (R2 = 0. 9963). Recovery and dilution experiments also 
showed a high correlations (R2 = 0.9963, R2 = 0.9579, respectively) and the intm-assay 
variability was satisfactory (<100/o). The inter-assay variability was relatively higher at 
23.04% which suggests that for reasons unknown something is affecting the binding of 
progesterone to the antibodies coating the tube differentially for each assay. Hematocrit 
was not taken into account in the present study as it was determined not to affect changes 
greater than the variability of the assay. Overall, the validation of the finger -prick blood 
assay confirms the usefulness of finger-prick blood sampling in the measurement of 
progesterone from blood. 
4.3 Menstrual Cycle Characteristics 
The present study investigated a total of33 menstrual cycles of 18 women 
volunteers. This study confirms the presence of menstrual cycle abnormalities reported 
in numerous studies (Table 1). Three of the eighteen women (16%) experienced cycles 
with a non-functional CL as determined by bloodspot analysis. This is similar to that 
reported by Prior et al. ( l990b) who documented at least one anovulatmy cycle in 19.6% 
of participating women. Prior et al. (1982) reported the incidence of anovulation in 33% 
of 48 cycles in 14 women as determined by temperature analysis. In the present study 
15% (5 of33) of cycles were anovulatory. This is less than half that reported by Prior et 
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al. (1982) however the present study used bloodspot data as the gold standard, and 
participants were on average 6 years younger. Smith eta/. (1984) reported the incidence 
ofSLP in fertile women to be 8% however in the present study SLP occurred in 66% (10 
of 15) of ovulating participants and in 43% of the ovulatory cycles (36% of all cycles), a 
percentage similar to Prior et al. (1982) who reported SLP in 500/0 of ovulatory cycles 
(33% of all cycles). Only about 36% of all cycles in the present study fit the criteria of a 
normal cycle with a functional CL. With the possible connection of menstrual cycle 
abnormalities to health problems such as infertility {Sherman & Korenman, 1974a), bone 
loss (Prior et al., 1990b ), and breast and endometrial cancer (Cowan et al., 1981; Coulam 
eta/.~ 1983) this finding reinforces the need to develop an easy-to-use and inexpensive 
method of determining menstrual functioning in women. The measurement of 
appropriate markers of luteal function in menstrual fluid is an idea that should be 
investigated further (See 4.6. Future research (Glycodelin)). 
4.4 Bloodspot and Temperature Analysis 
Bloodspot progesterone was used as the gold standard in the present study. 
When comparing the results obtained from bloodspot and temperature analysis some 
discrepancies were apparent Tbe sensitivity and specificity of the two methods were 
satisfactory however the negative predictive value for anovulation was low. 11mt is, the 
prediction of a non-functional cycle by both bloodspot and temperature was 
asynchronous. Prior (1997) has previously shown lack of molimina is sensitive and 
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specific in predicting anovulation. Prior et al. {1990a) validated the temperature method 
(Maximina ®) against the LH peak, however, it was not validated against serum 
progesterone. As only three finger -prick blood samples were taken during the luteal 
phase this disparity may be due to improper timing of bloodspot sampling. This is a 
common problem and one of the motivations for the present study. The release of 
progesterone is pulsatile and variable (Soules eta/.~ 1988) which makes the proper 
determination ofluteal function difficult It is quite possible that the finger-prick blood 
sampling strategy was insufficient to obtain samples with elevated progesterone 
concentrations in cycles with biphasic temperature patterns. The timing of the bloodspots 
relied on the participants observations of vaginal mucus changes. There was no 
difference in the scores for mucous secretion between ovulatory or anovulatory cycles, 
however the subjectivity of this parameter may have affected appropriate timing of blood 
sampling. Gaps in the luteal phase where no bloodspot sampling occurred may have 
hidden rises in progesterone where the samples taken showed low levels. Some samples 
were obtained very close to the first day of menses when progesterone values are 
expected to be lower. In future studies~ bJoodspot samples may have to be taken daiJy 
from mid-cycle (or maximal mucous secretion) onward. 
Unlike the bloodspot sampling, temperature readings were recorded daily. Other 
researchers have documented disparities in temperature and other detection methods of 
ovulation such as plasma progesterone measurements (Johansson et al., 1972). It is 
possible that the temperature analysis gave false results as problems can arise when 
technical errors occur or when temperature readings are improperly recorded Accuracy 
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and precision of the two types of thermometers used were tested Both were consistently 
precise and consistently less accurate (by --{).20°C) when compared to a reference 
thermometer. Thus it is probably unlikely that the thermometers were the sourq! of the 
disparity between the temperature and bloodspot analysis since the Maximina ® analysis is 
programmed to detect significant shifts in temperature. Each participant in the present 
study was instructed on how to take their temperature. This lessens the chances of 
inaccurate readings but it doesn,t abolish the possibility that errors could occur in 
temperature taking. When relying on data recorded by the participants this study 
assumed that the reported data were accurate. However. false data., missing data, or data 
recorded during an unrecorded illness or unusual awakening may affect the overall 
analysis. It is also possible that for some monophasic temperature cycles, ovulatory 
levels of progesterone for unknown reasons did not elicit measurable changes in 
temperature. Any of these situations may have contnouted to the disparity between 
bloodspot and temperature analysis. 
4.5 Diary Results 
In the present study, the scores of seven diary experiences were reported as 
significantly greater for cycles with a functional CL than those with a non-functional CL. 
Use of the ANOV A provided a functional tool in eliminating seemingly less useful 
information from the Menstrual Cycle Diary©. Results from the ANOVA indicated 
significant cyclic changes occurring within the cycle (comparing the 3 windows) and 
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which particular window (e.g. MC. EC, or 3D A) provided the least distinguishing data. 
For example, side breast tenderness scores were cyclical as determined by ANOV A. 
Mid-cycle scores for side breast tenderness were discarded from subsequent analyses 
comparing experiences between ovulatory versus anovulatory cycles because the scores 
from the EC and 3D A windows were significantly greater than scores from the MC 
window, which was close to the usual score of zero, meaning none (or not observed). It 
is evident then that when comparing side breast tenderness, scores from only those two 
windows (EC, 3D A) are necessmy to analyze. This can be utilized for aJJ items of the 
diary providing a simple and objective way oflooking at and comparing diary data. 
The experience of pain manifested as cramps was greater for ovulatory cycles 
than anovulatory cycles. Studies show that extracts from used tampons of dysmenorrheic 
women have a greater content of prostaglandins, which have been linked to rnenstruaJ 
pain, than do women without painful menstruation (Chan & Hill, 1978; Powell et al.~ 
1985). Pain may be caused by the formation of arachidonic acid derivatives 
(prostaglandins, thromboxanes,. and leukotrienes) in the uterus (Bieglmayer et al.. 1995). 
It may be that the significant difference in scores may be due to higher prostaglandin 
levels in ovulatory cycles. Prostaglandin levels are UJrregulated by way of progesterone 
withdrawal during the late luteal phase (Fraser, 1999) and are synthesized by luteal cells 
of the corpus luteum. Interestingly. Laessle et al. (1990) found that pain symptoms 
increased with decreasing progesterone levels. Studies show that the use of oral 
contraceptives which prevent ovulation (i.e. no formation ofCL) reduces prostaglandin 
levels (Bieglmayer eta/., 1995) which proposes the possibility that perhaps anovulatory 
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cycles may have lower prostaglandin levels thus explaining the lesser menstrual pain 
observed by women with anovulatory cycles. 
Side breast tenderness was greater for those experiencing cycles with a functional 
CL. Scores for breast tenderness tend to be maximal in the mid-to-late luteal phase of the 
menstrual cycle and with ovulatory women (Beumont et al.~ 1975; Laessle et al., 1990; 
Hale eta/., 2003). Hale eta/. (2003) found cyclicity in front breast tenderness in mid-life 
women. The present study found tenderness of the side breast to be greater in ovulatory 
cycles and did not find the same for front breast tenderness. Higher levels of urinary 
estrone and lower luteal phase progesterone excretion have been documented in 
perimenopausal women (Santoro et al., 1996). This has been suggested to be associated 
with front breast tenderness in perimenopausal women (Hale et al., 2003). Wang et al. 
(1996) suggested higher estradiol and lower progesterone levels were associated with 
breast tenderness in women with premenstrual syndrome when compared to controls. 
The relationship between breast tenderness and estrogen cannot be determined from the 
present study. 
Change in breast size was also perceived to change more for ovulatory cycles than 
anovulatory cycles. Morphological changes of the human breast correlate with menstrual 
phase (Vogel et al., 1981; Battersby et aL, 1992; Ramakrishnan eta/., 2002). 
Progesterone's action on the breast is, at least in the short tenn (Chang et al.~ 1995). 
proliferative causing a transient swelling of the breasts. Feuerstein & Shaw (2002) 
describe the experiences of breast swelling and tenderness as suggestive of fluid retention 
which they found to score highest in the luteal phase. In the present study. fluid retention 
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was found to score higher for those with ovulatory cycles. It has been suggested that 
water-retaining hormones such as estrogen, angiotensin/aldosterone, and prolactin among 
others may mediate retention of fluid (Feuerstein & Shaw, 2002). Whether cycles with a 
non-functional CL lack the hormonal environment to influence changes in fluid retention, 
and/or breast swelling and tenderness needs to be investigated further. The results from 
the present study, however, do suggest differences to this effect. 
Feelings of anxiety, depression, and frustration are often grouped under the 
category of mood The results of investigations into the so-called menstrual cycle phase-
dependent alterations of these behaviours have been mixed~ some reports document 
cyclicity while others do not (Little & Zahn, 1974; Beumont et al., 1875; Both-Orthman 
et al., 1988~ Laessle et al., 1990). In the present study, feelings of depression and 
fiustration scored significantly higher for those with ovulatory cycles than those with 
anovulatory cycles suggesting that the hormonal fluctuations that occur during a normal 
cycle contribute to these psychological changes. 
Research on the relationship between sleep and the menstrua] cycle has also been 
contradictory (Laessle et al., 1990; Driver et al., 1996; Baker & Driver, 2004). More 
sleep cycles have been documented in the luteal phase of the menstrua] cycle (Le Bon et 
al, 2002). This increase may heighten a woman's sensitivity to dysphoric experiences 
during the luteal phase (LeBon et al. 2002). In the present study~ those with ovulatory 
cycles observed more sleep problems than those with anovulatory cycles. There was no 
significant change, however, in scores for sleep problems for any of the three windows in 
the present set of ovulatory cycles (i.e. all windows were used in the analysis). Hale et 
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al. (2003) also did not find any statistical difterence in scores across the three cycle 
windows they investigated. An increase in sleep problems for women experiencing 
ovulatory cycles may be real. However, more research is needed to corroborate these 
findings. 
One purpose of the Menstrual Cycle Diary© is to discover whether emotional or 
physical experiences observed throughout the menstrual cycle differ for women with 
functional or non-functional cycles. This information may be useful in determining luteal 
function in the absence of other detection methods. Magyar eta/. (1978) has concluded 
that women presenting a history of regular cycles (as determined by length) in the 
company of premenstrual molimina can be identified as ovulatory. This may in fact be 
correct, however, due to the complexity of the menstrual cycle more research is 
warranted. In the present study seven experiences scored statistically higher for women 
with ovulatory cycles. The comparison of functional cycle scores with the small sample 
of non-functional cycle scores decreases the power of the findings and it may be that 
differences not found may actually exist. Theretbre, it would be inappropriate to assume 
that the insignificant findings are absolute. 
4.6 Future Research (Glycodelin) 
The results from the present study suggest that progesterone may not be an 
appropriate marker to determine luteal function from menstrual fluid. The measurement 
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of additional markers that reflect progesterone~s action may be a more suitable avenue of 
investigation. One such marker is glycodelin. 
Glycodelin, also called PP14, is a 28 kDa glycoprotein belonging to the lipocalin 
superfamily expressed in the uterus, faiJopian tubes, ovary, and breast among other 
tissues (Seppala et al., 2002). The expression of glycodelin in the endometrium appears 
to be menstrual phase-dependent, with near absent levels during the proliferative phase 
and rising levels during the secretory phase peaking during late luteal phase (Julkunen et 
al., 1986a; Li eta/., 1993). Even though progesterone and glycodelin Jack correlation in 
circulating levels (glycodelin's rise is later than progesterone's and is maintained until the 
first few days of the following cycJe) glycodelin' s synthesis is said to be reguJated by 
progesterone (Rutanen et al., 1987; Seppala et !d., 2002). This is suggested due to the 
observation that anovulatory cycles show low levels of both progesterone and glycodelin 
throughout the menstrual cycle (Rutanen et al., 1987; Seppala et al .• 2002). Glycodelin is 
measurable in serum and uterine flushings; however, serum levels of this protein do not 
accurately reflect luteal function (Batista et !d., 1993a; Batista et al., 1 993b ). The idea of 
mea.~uring glycodelin to determine luteal function is not a new one (Batista et al., 1993b; 
Julkunen et al., 1986b; Fay et al., 1990; Dalton et al., 1998), however, its measurement in 
menstrual fluid has not been, to the knowledge of the authors of the present study, 
investigated for this purpose. 
Preliminary work from the laboratory of the preSent study showed that glycodelin 
may be measurable in menstrual fluid extracted from used tampons. Two used tampons 
were extracted and analyzed for glycodelin using the western blot technique (See 
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Appendix C). Unfortunately, the luteal status of the cycle for which these samples were 
collected was not determined The extraction procedure involved soaking the used 
tampons overnight in phosphate bufter saline (0.89%, PBS) at 4°C, centrifuging the 
extract for 10 min (3000 rpm), centrifuging ~20 ml through a filter device (Centricon 
Plus-20, Millipore) for about an hour until all the fluid has been centrifuged through the 
filter (3200 x g, 25°C), inverting tbe fiJter cup and centrifuging again for one minute 
(1 000 x g, 25°C), and saving and storing the concentrated sample at -20°C. Protein 
separation and transfer was carried out using SDS-PAGE and western blot Glycodelin 
was generously donated by Dr. Glenn Braunstein's laboratory (USA) with the permission 
of Dr. B0rge Teisner (Denmark). Impurities in the long-stored protein samples, however, 
made for an unsuccessful control (not shown). The use of a purified protein sample, 
preferably from amniotic fluid as it is an excellent source of this protein, wouJd be 
necessary for control purposes. Further research is needed to confirm the usability of 
glycodelin from menstrual fluid as a marker of luteal function. 
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APPENDIX A 
Consent Forms, Menstrual Cycle Diary©, Explanation Sheet 
~=---------------------
CydeDay 1 2 3 4 5 6 7 
Date 
Tampons/pads/day 
8 
Menstrual Cycle Diary 
Month: 
9 10 11 12 13 14 15 16 
Year. ___ _ 
17 18 19 2t) 21 22 23 24 25 26 27 28 29 
Record 0 = none, 1 = minim~ l = moderate, 3 = moderately intense, 4 = very intense 
Amount Row 
Cramps 
Breast Sore: Front 
Breast Sore: Side 
Auid Retention 
Mucous secretions 
Constipation 
Headache 
Sleep Problems 
Feeling Frustrated 
Feeling Depressed 
Feeling .Anxious 
Record M = much less, L = a little less, U = uswal, Y = a little increa~ Z = much increased 
Appetite 
Breast Size 
Interest In Sex 
Feeling Of Energy 
Feeling Of Self-Worth 
Outside Stresses 
Basal Temperature 
Comments 
(tempera.ture taken 
late. feeling sick, poor 
sleep, eic} 
JC Prior, Copyright 1990 
30 31 
Faculty of Medicine 
Memorial University of Newfoundland 
Consent to Take Part in Health Research 
Consent Form 
Revised !001/12 
TITLE: Noninvasive Assessment of Menstrual Cycle Hormone Levels 
INVESTIGATOR(S): Sarah J. Halfyard, Donald McKay Ph.D, Dr. Jerilynn Prior M.D. 
You have volunteered to take part in a research study. It is important that procedures and 
tests are thoroughly explained to you and any questions and concerns addressed. This 
consent form explains the study. 
As a volunteer, you are free to withdraw from the study at any time. 
The researchers will: 
• discuss the study with you 
• answer your questions 
• keep confidential any information which could identify you personally 
• be available during the study to deal with problems and answer questions 
1. Introduction/Background: 
Often, ovulation is assumed to occur when menstrual cycles are regular. However, ovarian 
disturbances (short luteal phase [ <10 days], anovulatory cycle [failure to ovulate], short/long 
cycle length) have been documented in healthy women who report regular cycles. Previous 
research has implicated ovarian disturba."lces with the development of infertility, 
osteoporosis, breast cancer, and heart disease. Current ovulation detection methods tend to 
involve any one or all of the following problems: are not reliable, are hard to do, are 
uncomfortable or invasive and are expensive. 
This study proposes to document hormone levels obtained from sanitary products (tampons) 
obtained during the menstrual flow. The method is easy to remember and doesn't involve 
any invasive testing. Potentially this new method could be used to document how 
commonly ovarian disturbances happen in the general population of women. If proven 
accurate, this method could be used cycle by cycle over many years to advance our 
understanding of menstrual cycle variability. 
2. Purpose of study: 
The purpose of this study is to develop and validate a noninvasive method to determine 
hormonal, ovulatory and luteal function (i.e. function of the ovaries) of women by 
documenting hormone levels in finger-pricks and in menstrual flow. 
Initials: __ _ 
3. As a participant you understand that you are agreeing to do the following: 
a) Answer background questions regarding your health and history of menstruation and 
reproduction 
b) Keep a daily Menstrual Cycle Diary for a three month period noting what you observe every 
day in the chart provided to you 
c) Record morning temperature in your mouth first thing in the morning for a three-month 
period. You understand that the digital thermometer will be yours to keep if you finish the 
study 
d) Have blood finger-prick samples taken daily for three days about 10-14 days after your 
period starts, about a week later and the first day of your period each month for two months 
e) Monitor vaginal stretchiness of mucus and notify the principal investigator as soon as 
possible when maximal stretchiness of mucus is observed 
f) Collect all used tampons during the first two full days of flow and storing them in your 
freezer in the containers that are provided to you. You will do this for three consecutive 
menstrual periods 
4. Length of time: 
You are participating in a three-month study. It will take about an hour at first to learn about 
the Menstrual Cycle Diary and to complete the questionnaires about your health, habits, past 
health and menstrual cycles. It will take r..o more than 2 minutes of your time each morning 
to take your temperature and usually no more than 3 minutes each day to fill out the daily 
Menstrual Cycle Diary. The investigator will come to your home or you may meet at the 
Health Sciences Centre for the finger-prick blood sampling, which should take no more than 
5 minutes. 
5. Benefits: 
We cannot guarantee that participation in the study will benefit you personally. 
6. Risks, Discomforts and Inconveniences: 
.... 
You are asked to complete the daily Menstrual Cycle Diary during the entire duration of the 
study as well as collect basal temperature readings. You will collect used sanitary products 
during the first two days of flow for the entire three cycles. Finger prick blood samples will 
be taken daily for a total of seven days each cycle for two cycles. The finger-prick blood 
sampling is quick and easy and resultsin minimal discomfort. 
Initials: __ _ 
7. Liability statement: 
Signing this form gives us your consent to be in this study. It tells us that you understand 
the information about the research study. When you sign this form, you do not give up your 
legal rights. Researchers involved in this research study also still have their legal and 
professional responsibilities. 
8. Confidentiality: 
Unless required by law or hospital policy, only the principal investigator may have access to 
any confidential documents pertaining to your participation in this study that may identify 
you by name. Furthermore, your name will not appear in any report or article published as a 
result of this study. 
Questions: 
You have been given a copy of this consent form. 
If you have any questions about taking part in this study, you can meet with the investigator 
who is in charge of the study. That person is: 
Sarah J. Halfyard- (709) 738-2009 or (709) 777-8565 
Or you can talk to someone who is not involved with the study at all, but can advise you on 
your rights as a participant in a research study. This person can be reached through: 
Office of the Human Investigation Committee (HI C) at 709-777-6974 
Email: jennifem@mun.ca 
• Exclusion of women who are pregnant or not regularly menstruating. Women who 
have significant he~lth problems are also excluded. Women who are taking 
reproductive hormones including the birth control pill or shots are also not eligible. 
This study intends to document hormone levels of the menstrual cycle. 
If you are pregnant you cannot take part in this study. 
If intending to participate in this st1.1dy you must have stopped taking any reproductive 
hormones (such as oral contraceptives (birth control pills), hormone patches, or other 
kinds ofhormone therapy) at least 6 months before the start of this study. You must not 
take reproductive hormones at any time throughout the study. 
If you do become pregnant or begin taking reproductive hormones during the study 
period you must immediately inform the study investigator. 
Initials: __ _ 
Signature Page 
Study title: Noninvasive Assessment of Menstrual Cycle Hormone Levels 
Name of principal investigator: Sarah J. Halfyard 
To be filled out and signed by the participant: 
You have read the consent form [and information sheet]. 
You have had the opportunity to ask questions/to discuss this study. 
You have received satisfactory answers to all of your questions. 
You have received enough information about the study. 
You understand that you are free to withdraw from the study 
• at any time 
• without having to give a reason 
Please check as appropriate 
Yes {} 
Yes {} 
Yes {} 
Yes {} 
Yes {} 
No {} 
No {} 
No {} 
No {} 
No {} 
You understand that it is your choice to be in the study and that you may not benefit. 
You agree to take part in this study. 
Signature of participant 
Signature of witness 
To be signed by the investigator: 
Date 
Date 
Yes {} 
Yes {} 
No {} 
No {} 
I have explained this study to the best of my ability. I invited questions and gave answers. I 
believe that the participant fully understands what is involved in being in the study, any potential 
risks of the study and that she has freely chosen to be in the study. 
Signature of investigator Date 
Telephone number: (709) 738-2009 or (709) 777-8565 
Initials: _. __ 
TITLE: 
Faculty of Medicine 
Memorial University of Newfoundland 
Consent to Take Part in Health Research 
Non-invasive assessment of menstrual cycle hormone levels 
Revised 2002/04 
INVE~TIGATOR(S): Sarah J. Halfyard, Donald W. McKay, Ph.D., Jerilynn C. Prior, M.D. 
You have been asked to take part in a research study. It is up to you to decide whether to 
be in the study or not. Before you decide, you need to understand what the study is for, 
what risks you might take and what benefits you might receive.· This consent form explains 
the study. 
As a volunteer, you are free to withdraw from the study at any time. 
The researchers will: 
• discuss the study with you 
• answer your questions 
• keep confidential any information which could identify you personally 
• be available during the study to deal with problems and answer questions 
1. Purpose of study: 
The purpose of the study is to compare progesterone levels from finger-prick blood spots 
with progesterone levels from blood sampling. Similar readings will demonstrate the 
suitability of the finger-prick method as an accurate alternative to venous blood sampling. 
2. As a participant you understand that you are agreeing to do the following: 
a) To share the phase or cycle day of your menstrual cycle or term of pregnancy with the 
investigator 
b) To provide, sequentially, up to 8 drops ofblood by the finger-prick method and 6 teaspoons 
ofblood by the venous sampling method. You will be asked to do this up to two times 
during different phases of your menstrual cycle (once during the late follicular phase and 
once during the mid-luteal phase). If you are pregnant, you will be asked to donate the blood 
and serum samples only once. 
Initials: _.:____ 
3. Length of time: 
You are asked to provide finger-prick blood spot samples and a venous blood sample up to 
two times. It should not take more than 10 minutes to complete the spot test and blood 
collection each time. 
4. Possible risks and discomforts: 
The finger-prick blood sampling methcd is quick and easy and resui.ts in minimal 
discomfort. Blood collection by the venous sampling method results in minor discomfort 
and takes no more than 5 minutes to complete. 
5. Benefits: 
This study will not benefit you personally. 
6. Liability statement: 
Signing this form gives us your consent to be in this study. It tells us that you 
understand the information about the research study. When you sign this form, you do 
not give up your legal rights. Researchers or agencies involved in this research study 
still have their legal and professional responsibilities. 
7. Confidentiality: 
Unless required by law or hospital policy, only the principle investigator, Sarah J. Halfyard, 
may have access to any confidential documents pertaining to your participation in this study 
that may identify you by name. Furthermore, your name will not appear in any report or 
article published as a result of this study. 
8. Questions: 
You have been given a copy of this consent form. 
If you have any questions about taking part in this study, you can meet with the investigator 
who is in charge of the study at this institution. That person is: 
Sarah J. Halfyard at 709-777-8565 
Or you can talk to someone who is not involved with the study at all, but can advise you on 
your rights as a participant in a research study. This person can be reached through: 
Office of the Human Investigation Committee (HIC) at 709-777-6974 
Email: hic@mun.ca 
Initials:_:..___ 
• Exclusion of women who are not regularly menstruating. Women who have 
significant health problems are also excluded. Women who are taking reproductive 
hormones including the birth control pill or shots are also not eligible. 
This study intends to doGument the progesterone concentrations from blood spots and 
serum. 
If intending to participate in this study you must have stopped taking any reproductive 
honnones (such as oral contraceptives (birth control pills), honnone patches, or other 
kinds of honnone therapy) at least 6 months before the start of this study. You must not 
take reproductive honnones at any time throughout the study. 
If you begin taking reproductive honnones during the study period you must 
immediately infonn the study investigator. 
Initials: __ _ 
Signature Page 
Study title: Non-invasive assessment of menstrual cycle hormone levels 
Name of principle investigator: Sarah J. Halfyard 
To be filled out and signed by the participant: 
I have read the consent [and information sheet]. 
I have had the opportunity to ask questions/to discuss this study. 
I have received satisfactory answers to all of my questions. 
I have received enough information about the study. 
I understand that I am free to withdraw from the study 
• at any time 
• without having to give a reason 
Please check as appropriate 
Yes {} 
Yes {} 
Yes {} 
Yes {} 
Yes {} 
No {} 
No {} 
No {} 
No {} 
No {} 
I understand that it is my choice to be in the study and that I may not benefit. Yes { } No {} 
I agree to take part in this study. Yes {} No {} 
Signature of participant Date 
Signature of witness Date 
To be signed by the investigator: 
I have explained this study to the best of my ability. I invited questions and gave answers. I 
believe that the participant fuily understands what is involved in being in the study, any potential 
risks of the study and that he or she has freely chosen to be in the study. 
Signature of investigator Date 
Telephone number: (709) 777-8565 
Initials: 
---'---
CONFIDENTIAL 
Noninvasive Assessment of Ovarian Cycle Hormone Levels 
Explanation Sheet 
Often, ovulation (release of an egg) is assumed to occur in women who have 
regular menstrual cycles. However, despite regular cycle length (21-36 days) ovulation 
may not occur. Furthermore, ovarian hormone production, especially progesterone, may 
be inadequate. Ovarian disturbances (i.e. short luteal phase [ <l 0 days], anovulatory 
cycles, short/long cycle length) have been implicated in future health problems such as 
osteoporosis and breast cancer. Current ovulation detection methods can be variably 
reliable, tedious and inconvenient as well as invasive and expensive. Therefore, an easy-
to-use, inexpensive, reliable, and noninvasive method to determine luteal function in 
women is needed. 
The ovarian cycle has an average length of28 days. The cycle is divided into two main 
phases: the follicular phase and the luteal phase. The follicular phase is characterized by 
a steady increase in blood levels of the ovarian hormone, estradiol, and a very low 
(almost absent) level of progesterone. During this phase the ovarian follicle that contains 
the oocyte begins to change and grow due to exposure to estradiol and the anterior 
pituitary hormone, follicle-stimulating hormone (FSH). Estradiol also causes the uterine 
endometrium to proliferate during this phase and vaginal mucous to become abundant 
and stretchy. At about mid-cycle (day 14), a surge in the release ofthe anterior pituitary 
hormone, lutenizing hormone (LH), precedes ovulation by a few hours. Ovulation marks 
the beginning of the luteal phase. 
The luteal phase commonly lasts about 10-16 days and is characterized by a 
dominant progesterone presence and a lower but still significant blood level of estradiol. 
The remaining ruptured follicle transforms into the corpus luteum, which secretes 
progesterone. During this phase the endometrium takes on more secretory properties in 
preparation for possible implantation of an embryo. The corpus luteum functions for 
about two weeks and in the absence of pregnancy will degenerate at the end of the two-
week period. A decline in blood hormone levels ensues with the resultant sloughing off 
of the endometrium as menstrual flow. The first day of menstrual flow is considered the 
beginning of a new cycle. 
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Progesterone has various effects on the body. One in particular is its effect on 
body temperature. Progesterone travels in the blood to reach the brain and acts on areas 
of the brain, such as the hypothalamus, that control temperature. During the follicular 
phase the temperature is relatively steady. Increased concentrations of progesterone in 
the luteal phase cause a small rise in basal (resting) body temperature (0.2-0.5 °C). The 
measurement of first morning temperature is used to determine whether a woman has 
ovulated during that cycle and if she has, the length of the luteal phase, which should be 
10-16 days. The temperature data are analyzed with least squares statistics to determine 
the date of temperature rise and the length of the luteal phase. 
Collecting menstrual tampons: 
Day l is considered the first day of your menstrual flow. On this day, you will 
begin to fill out the daily Menstrual Cycle Diary form. Menstrual tampons will be 
collected during your next three menstrual flows. Tampons will be provided for you. 
Please refrain from using tampons of a different brand during the study period. You will 
be provided with opaque, screw top containers and a marker. Each time you change your 
tampon place it in a container sealing it well. Label the container with your code#, the 
date and time. Then place the container in the freezer. When your menses is over, 
telephone the principal investigator, Sarah, at 738-2009 or 777-6585 so that arrangements 
can be made for the pick up of the samples and data sheets. 
Blood sample collection: 
Finger prick blood samples will be collected for 3 consecutive days at the onset of 
stretchy vaginal mucous (which, if you look at the above diagram, is just before the 
highest point for estmg~n). We will coi.l~::ct again for the 3 consecutive days about a 
week later (when we are trying to catch the peak of progesterone) and once on the first 
day of your period (to compare with what we measure from your tampons). Finger prick 
blood sampling will be performed during your last two cycles of the three-month study 
period. Blood sampling can be performed at your home or at the Health Sciences Centre. 
Upon the observation of maximal mucous stretchiness, immediately contact the principal 
investigator, Sarah, at 738-2009 or 777-8565. 
UNDERSTANDING YOUR MENSTRUAL CYCLE 
. Or JC Prior@ 1·991, 2002 
The menstrual cycle is created by over a dozen hormones changing in a complex and coordinated manner. Hormones of 
the ovary, pituitary, and uterus work together to create cyclic symptoms and signs during your cycle. Completing this · 
form every day will help you to learn from and to notice important features about your own menstrual cycle. 
At the top, write the month of the first day of flow (day 1 ). Please start filling in the form on the evening of the first day of 
your period. 
Be sure to write something in every box. A blank tells you nothing about that day but a 0 is good evidence you didn't 
experience it! If you forget, skip that day. Don't try to remember later. Use a new chart for each cycle. 
If no period occurs, continue recording on another sheet after day 30 and just re-number 1 to "31" for subsequent days 
until flow starts. If you have had no flow for several mon~hs, start using a new Diary sheet for each month. 
The scale at the top of this Diary is from 0 to 4; zero represents something you did not experience and four represents the 
worst it has ever been for you. The scale at the bottom uses letters to indicate as factors go up or down from your usual 
'(U)' or normal state. Although the form is mostly self-explanatory, a few explanations and samples are provided . 
.EUlw.:. 
Because flow is important, you are requested to provide two indicators for it. The first is the number of regular sized, 
soaked pads and/or tampons you use each day of flow. If you use a combination of pads and tampons, enter the 
combined total for that day (4 tampons/3 pads= 7). The second is your assessment of flow. The score goes from 0 = 
none, 1 =spotting, to 4 which means clots or a change every hour. 
Name: Month: A~rr.h Year: 99 
Cycle Day 1 2 3 4 5 slrlslg 10 11 12 13 14 15 16 17 18 19 
Date 12 13 14 15 16 Continued 
Tampons/pads/day 4 4 3 2 0 I I I 
Record 0 = none, 1 = minimal, 2 = moderate, 3 = moderately intense, 4 = very intense 
Breast Tenderness· 
Breasts can tell us a lot about estrogen and progesterone levels and how they 
are acting. You are being asked to note both front and/or side breast 
tenderness. In the diagram there is shading in the general areas of your breast 
that you should touch firmly with the palm of your hand to determine if you have 
any breast soreness or sensitivity there. There may be very little soreness (a 
front 
tenderness 
Fluid Retention· 
side 
tenderness "1 H) but that pressure will feel different from the way the same pressure feels 
on your leg, for example. 
This means feeling bloated or puffy or water weight gain and getting up to urinate at night. 
Mucous Secretions· 
The mouth of the uterus (cervix) makes a clear stretchy fluid when estrogen levels are high. Progesterone levels stop the 
production of stretchy mucous A "4" means you can stretch the mucus out for 6-8 em (3-4 inches). 
Record 0 = none, 1 = minimal, 2 = moderate, 3 = moderately intense, 4 = very intense 
Amount Flow 3 4 2 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
~ramps 4 2 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 
Breast Tenderness: Front 0 0 0 0 0 0 0 0 0 0 0 0 1 3 2 0 0 0 
Breast Tenderness: Side 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
Fluid Retention 0 0 0 1 0 0 0 0 0 0 0 2 3 3 2 1 2 1 
Mucous Secretion 0 0 0 0 0 0 0 0 0 0 0 1 1 3 0 0 0 0 
1 
Headache· 
The score in this box is for any old ordinary kind of headache. However, if it was a migraine, put a small star or dot in the 
box as well as the score. 
Feelings and Outsjde Stresses· 
You are asked to record how you feel each day using a 0-4 scale on the top sectiun of tt.e form. In addition, we would 
like you to evaluate the amount of outside stress in your life (Stress- work, home, etc). These two things are sometimes 
different- your day may have been awful but you can still feel good about yourself and not depressed or anxious. 
Please write your comments at the bottom of the column. This may include any particular event that influenced how you 
felt that day (eg illness, a job promotion, winning a lottery, argument with partner). 
Record M = much less, L = a little less, U = usual, Y = a little increased, Z = much increased 
fA.ppetite L u u u u 
Breast Size u u u y y 
Interest in sex L u u y u 
Stress - work. home, etc L L u u y 
Quantitative Basal Temperature (QBT) Monitoring: (called this because we use statistics to decide where the 
temperature increase occurs-Prior, Clinical Invest Med., 1990). Progesterone makes the first morning temperature 
increase a small but reliable amount. 
The following recommendations will assist you to accurately take and record your oral temperature. 
1. Day 1 is the first day of your flow (and you should be starting on a new sheet). 
2. Take your temperature in the morning, when you first wake. 
3. Activity will raise your basal (resting) temperature. Although you may start your thermometer and head to the 
washroom, if you can, postpone this or getting out of bed until your temperature taking is finished. 
4. Under 'Comments', please record any events that may affect your morning temperature (the time if you slept in or got 
up early, felt like you were getting the flu or had a very late night). 
Using the digital thermometer: 
1. Press the ON/OFF button and a beep will sound (88.88 will display when the thermometer is used for the first time). 
2. After a few seconds the display will go blank. 
3. Place the thermometer under your tongue. 
4. When the peak temperature is reached (in about 1 minute), a beep will sound 3 times. The reading will not change 
while the power remains on. 
5. Tum the thermometer off by pressing the green ON/OFF button. The reading will be stored in memory for 3 seconds 
the next time you switch the thermometer on. After 3 seconds, the display will go blank and the temperature will be 
permanently erased from memory. 
Analyzing your temperature data: 
If you would like to figure out whether you have ovulated and the length of your luteal phase (the time following ovulation) 
you can do that. First, compute the average of all the temperatures in your record, by adtjing them up and dividing by the 
number of days for which you have temperature readings. The average temperature you get can then be compared with 
the actual readings. If your temperature went above and stayed above that average until the day before the next flow you 
have ovulated. The higher temperatures should last 10-16 days. When there are between 3 and 9 days of higher 
temperatures, you have what is called a short luteal phase. This means that you have ovulated but the time of 
progesterone elevation is too short. 
Enjoy the keeping of this daily Menstrual Cycle Diary and quantitative basal temperature record. You will learn new 
things about yourself! 
2 
APPENDIXB 
Gas Chromatography-Mass Spectrometry (GC-MS) Print-out Results. First print-out 
shows the results of GCMS of a progesterone standard ( ~0.3 mg/ml). The first chart 
shows the total ion counts over time. The greatest number of counts was at the 17 minute 
mark. Scan 1319 with the retention time of 17.569 min shows characteristic progesterone 
peaks at 124, 191,272, and 314. Scan 1337 with the retention time of 17.768 min 
revealed the greatest abundance of progesterone at the 312 cluster. The second print-out 
shows the results for a concentrated sample (lOX) of un-used (blank) tampon extracts. 
The first chart shows the total signal of the acetonitrile-extracted sample with peaks 
within the same time frame as the progesterone standard (17 min). Listed is the 
chromatogram of each ion present. Tested for the presence and abundance of 
progesterone-characteristic peaks within the specific time frame of the progesterone 
standard total ion peak revealed no signals characteristic of progesterone (see second 
graph). The last print-out shows the results ofthe concentrated (lOX) hexane-extracted 
sample. The presence of progesterone was also not apparent in that sample. 
Area Percent Report -- Sorted by Signal 
Information from Data File: 
File : C:\HPCHEM\1\DATA\PROSTD.D 
Operator : 1 winsor 
Acquired : 2 Sep 103 9:26 am usin~AcqMethod 
Sample Name: Q?rogesterone std -o.3mg/m!_) 
Mise Info : 0.5ul inj 
LWINSOR 
Vial Number: 1 
CurrentMeth: C:\HPCHEM\1\METHODS\LWINSOR.M 
ime--> 
Retention Time Area 
Total Ion Chromatogram 
16.707 2065844 
17.572 
17.776 
154346421 
11138089 
TIC: PROSTD.D 
Area % 
1.233 
92.119 
6.648 
20.00 
Ratio % 
1.338 
100.000 
7.216 
25.00 
. 
. 
File 
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Acquired 
Instrument 
Sample Name: 
Mise Info 
Vial Number: 
bun dance 
14000 
13000 
12000 
11000 
10000 
9000 
8000 
7000 
6000 
C:\HPCHEM\1\DATA\PROSTD.D 
1 winsor 
2 Sep 103 9:26 am using AcqMethod LWINSOR 
5970 - In 
progesterone std -o.3mgjml 
0.5ul inj 
1 
Scan 1337 (17.768 min): PROSTD.D 
91 
3 2 
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5000 
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4000 
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File : C:\HPCHEM\1\DATA\PROSTD.D 
Operator 1 winsor 
Acquired 2 Sep 103 9:26 am using AcqMethod LWINSOR 
Instrument : 5970 - In 
Sample Name: progesterone std -0.3mgjml 
Mise Info 0.5ul inj 
Vial Number: 1 
1 bundance 
180000 
Scan 1319 (17.569 min): PROSTD.D 
1 4 
170000 
160000 
150000 
140000 
130000 
120000 314 
110000 
100000 
90000 91 
79 
80000 
70000 55 272 229 
60000 
50000 191 
40000 147 
30000 1 0 
20000 244 
10000 
jz--> 
Area Percent Report -- Sorted by Signal 
Information from Data File: 
File C:\HPCHEM\1\DATA\SH2.D 
Operator : lwinsor 
Acquired : 16 Sep 103 9:46 am using AcqMethod LWINSOR 
Sample Name: Sarah H ~ (Aceto) 
Mise Info ~ 
Vial Number: 1 
CurrentMeth: C:\HPCHEM\1\METHODS\LWINSOR.M 
bundance TIC: SH2.D 
5000000 
Retention Time Area Area 9:-0 Ratio 9:-0 
Total Ion Chromatogram 
5.722 8380812 0.163 2.944 
6.539 8604037 0.168 3.022 
7.150 3500720 0.068 1.230 
7.431 2981529 0.058 1.047 
7.772 20525306 0.400 7.209 
8.127 5493844 0.107 1.930 
8.496 6315960 0.123 2.218 
8.786 5521833 0.108 1.940 
8.931 8072530 0.157 2.835 
9.083 90782087 1. 771 31.887 
9.327 24883777 0.485 8.740 
9.414 9245975 0.180 3.248 
9.504 22466841 0.438 7.891 
9.672 32686696 0.638 11.481 
10.095 18761580 0.366 6.590 
10.144 10117006 0.197 3.554 
10.256 52874403 1.031 18.572 
10.337 11374189 0.222 3.995 
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Area Percent Report -- Sorted by Signal 
Information from Data File: 
File C:\HPCHEM\1\DATA\SH2.D 
Operator lwinsor 
Acquired : 16 Sep 103 9:46 am using AcqMethod LWINSOR 
Sample Name: Sarah H 1 (Aceto) 
Mise Info 
Vial Number: 1 
CurrentMeth: C:\HPCHEM\1\METHODS\LWINSOR.M 
Retention Time Area Area % Ratio % 
10.399 5811125 0.113 2.041 
10.516 36749292 0.717 12.908 
10.674 109004478 2.126 38.287 
10.823 29441642 0.574 10.341 
10.868 38691944 0.755 13.590 
11.054 43764159 0.854 15.372 
11.122 19390452 0.378 6.811 
11.225 166118883 3.241 58.348 
11.328 31868647 0.622 11.194 
11.409 14111442 0.275 4.957 
11.479 42713699 0.833 15.003 
11.581 51668557 1.008 18.148 
11.734 93034314 1.815 32.678 
11.874 243321161 4.747 85.465 
11.969 32794638 0.640 11.519 
12.055 48735919 0.951 17.118 
12.133 184218947 3.594 64.706 
12.287 149523933 2.917 52.519 
12.468 21730077 0.424 7.633 
12.527 53982209 1.053 18.961 
12.585 27304163 0.533 9.590 
12.713 205001518 3.999 72.005 
12.851 34261397 0.668 12.034 
12.894 27524116 0.537 9.668 
13.146 107581063 2.099 37.787 
13.355 145991131 2.848 51.278 
13.438 33906868 0.661 11.910 
13.553 65931731 1.286 23.158 
13.644 98180104 1.915 34.485 
13.903 284703628 5.554 100.000 
14.118 204457097 3.989 71.814 
14.319 31248157 0.610 10.976 
14.443 72753207 1.419 25.554 
14.731 228078816 4.449 80.111 
14.938 82999169 1.619 29.153 
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Area Percent Report -- Sorted by Signal 
Information from Data File: 
File C:\HPCHEM\1\DATA\SH2.D 
Operator lwinsor 
Acquired 16 Sep 103 9:46 am using AcqMethod LWINSOR 
Sample Name: Sarah H 1 (Aceto) 
Mise Info 
Vial Number: 1 
CurrentMeth: C:\HPCHEM\1\METHODS\LWINSOR.M 
Retention Time Area Area % Ratio % 
15.125 25642084 0.500 9.007 
15.383 87883630 1.714 30.868 
15.712 148537156 2.898 52.173 
15.823 57225034 1.116 20.100 
15.978 37919253 0.740 13.319 
16.130 283954173 5.539 99.737 
16.567 214223888 4.179 75.245 
16.938 123461003 2.408 43.365 
17.047 54896786 1.071 19.282 
17.462 48489334 0.946 17.032 
17.937 166245818 3.243 58.393 
18.252 31034607 0.605 10.901 
18.503 31840069 0.621 11.184 
19.030 31972055 0.624 11.230 
19.439 23585446 0.460 8.284 
19.606 72963068 1.423 25.628 
20.312 12324524 0.240 4.329 
21.025 76773995 1.498 26.966 
21.456 15300028 0.298 5.374 
21.697 37487805 0.731 13.167 
23.422 28976083 0.565 10.178 
25.964 13675740 0.267 4.804 
27.435 36384624 0.710 12.780 
30.823 56175471 1.096 19.731 
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File 
Operator 
Acquired 
Instrument 
Sample Name: 
Mise Info 
C:\HPCHEM\1\DATA\SH2.D 
lwinsor 
16 Sep 103 9:46 am using AcqMethod LWINSOR 
5970 - In 
Sarah H 1 (Aceto) 
Vial Number: 1 
bundance 
17000 
16000 
15000 
14000 
13000 
12000 
11000 
10000 
9000 
8000 
7000 
6000 
5000 
ime--> 
Ion 314.00 {313.70 to 314.70): SH2.D 
Ion 272.00 (271.70 to 272.70): SH2.D 
Ion 191.00 (190.70 to 191.70): SH2.D 
Ion 124.00 (123.70 to 124.70): SH2.D 
16.50 17.00 17.50 18.00 
Area Percent Report -- Sorted by Signal 
Information from Data File: 
File C:\HPCHEM\1\DATA\SH1.D 
Operator : lwinsor 
Acquired 16 Sep 103 8:40 am using AcqMethod LWINSOR 
Sample Name: Sarah H 1 (hex) 
Mise Info : 
Vial Number: 1 
CurrentMeth: C:\HPCHEM\1\METHODS\LWINSOR.M 
bundance TIC: SH1.D 
6000000 
4000000 
2000000 
0 
ime--> 5.00 10.00 15.00 
J. J."" um-uW sP omcm~ 
'-------------------------·---------·---------··-
Retention Time Area Area o. Ratio ~ "0 0 
Total Ion Chromatogram 
7.786 2644222 0.029 0.406 
8.148 5936108 0.066 0.911 
8.804 10365142 0.115 1.590 
8.955 12312462 0.136 1.889 
9.108 182949992 2.025 28.073 
9.186 8260904 0.091 1.268 
9.254 7780817 0.086 1.194 
9.353 35239048 0.390 5.407 
9.438 19443252 0.215 2.983 
9.539 20841736 0.231 3.198 
9.694 53166736 0.589 8.158 
9.908 9405683 0.104 1.443 
10.033 18834793 0.209 2.890 
10.125 14466761 0.160 2.220 
10.168 10296535 0.114 1.580 
10.278 91994821 1.018 14.116 
10.354 9017185 0.100 1.384 
10.412 19558935 0.217 3.001 
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Area Percent Report -- Sorted by Signal 
Information from Data File: 
File C:\HPCHEM\1\DATA\SH1.D 
Operator : lwinsor 
Acquired 16 Sep 103 8:40 am using AcqMethod LWINSOR 
Sample Name: Sarah H 1 (hex) 
Mise Info 
Vial Number: 1 
CurrentMeth: C:\HPCHEM\1\METHODS\LWINSOR.M 
Retention Time Area Area % Ratio % 
10.485 16340727 0.181 2.507 
10.537 25523226 0.283 3.916 
10.691 82471897 0.913 12.655 
10.844 78698420 0.871 12.076 
11.146 62045996 0.687 9.521 
11.239 122745497 1.359 18.835 
11.348 21903957 0.242 3.361 
11.382 14273808 0.158 2.190 
11.467 47779092 0.529 7.331 
11.613 25456942 0.282 3.906 
11.757 109848987 1.216 16.856 
11.871 49864650 0.552 7.652 
12.138 103720007 1.148 15.915 
12.253 16620799 0.184 2.550 
12.307 112788845 1.249 17.307 
12.492 26891726 0.298 4.126 
12.725 109116752 1.208 16.743 
12.827 57071707 0.632 8.757 
12.915 29619016 0.328 4.545 
13.042 16150884 0.179 2.478 
13.102 13811448 0.153 2.119 
13.375 86154886 0.954 13.220 
13.468 171397751 1.898 26.300 
13.957 209922952 2.324 32.212 
14.129 90209783 0.999 13.842 
14.231 64119459 0.710 9.839 
14.559 138475627 1.533 21.248 
14.673 83765499 0.927 12.853 
14.743 66243918 0.733 10.165 
14.868 49491126 0.548 7.594 
14.939 122082378 1.352 18.733 
15.202 225139370 2.493 34.547 
15.375 85255052 0.944 13.082 
15.452 96074389 1.064 14.742 
15.591 96260598 1.066 14.771 
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Area Percent Report -- Sorted by Signal 
I 
Information from Data File: 
File C:\HPCHEM\1\DATA\SH1.D 
Operator : lwinsor 
Acquired 16 Sep 103 8:40 am using AcqMethod LWINSOR 
Sample Name: Sarah H 1 (hex) 
Mise Info : 
Vial Number: 1 
CurrentMeth: C:\HPCHEM\1\METHODS\LWINSOR.M 
Retention Time Area Area % Ratio % 
15.762 41350017 0.458 6.345 
16.002 651696452 7.215 100.000 
16.180 44043857 0.488 6.758 
16.285 180778018 2.001 27.740 
16.418 102240708 1.132 15.688 
16.541 105578999 1.169 16.201 
16.705 80378499 0.890 12.334 
16.972 31650487 0.350 4.857 
17.233 597755859 6.618 91.723 
17.441 37805497 0.419 5.801 
17.556 109755523 1.215 16.842 
17.622 46090056 0.510 7.072 
17.682 57779796 0.640 8.866 
17.900 122650227 1.358 18.820 
18.064 61206213 0.678 9.392 
18.264 96665860 1.070 14.833 
18.704 427347237 4.731 65.575 
18.902 39341511 0.436 6.037 
19.112 111702282 1.237 17.140 
19.700 547946938 6.066 84.080 
20.000 76333021 0.845 11.713 
20.148 27539624 0.305 4.226 
20.520 276177515 3.058 42.378 
20.696 23457789 0.260 3.599 
21.716 404821353 4.482 62.118 
22.075 93606870 1.036 14.364 
22.329 19382879 0.215 2.974 
23.172 29388268 0.325 4.510 
23.382 20203287 ~~~t~ 31~9~9 23.845 46089445 214883255 
24.167 19089249 
24.378 17403218 0.193 2.670 
24.658 0.202 2.794 18206705 24.850 192493041 2.131 29.537 26.239 
Tue sep 1 6 09:39:27 2003 
Page 3 
C:\HPCHEM\1\DATA\SH1.D 
Area Percent Report -- Sorted by Signal 
Information from Data File: 
File C:\HPCHEM\1\DATA\SH1.D 
Operator : lwinsor 
Acquired : 16 Sep 103 8:40 am using AcqMethod LWINSOR 
sample Name: Sarah H 1 (hex) 
Mise Info 
Vial Number: 1 
CurrentMeth: C:\HPCHEM\1\METHODS\LWINSOR.M 
Retention Time Area Area % Ratio % 
26.276 144909787 1.604 22.236 
26.846 25125547 0.278 3.855 
27.279 116205583 1.287 17.831 
27.619 50415251 0.558 7.736 
29.790 211024059 2.336 32.381 
30.909 17844303 0.198 2.738 
34.116 71466437 0.791 10.966 
37.804 92192175 1.021 14.146 
39.594 30246983 0.335 4.641 
44.072 40531454 0.449 6.219 
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C:\HPCHEM\1\DATA\SHl.D 
lwinsor 
: 16 Sep 103 
File 
Operator 
Acquired 
Instrument 
Sample Name: 
8:40 am using AcqMethod LWINSOR 
5970 - In 
Sarah H 1 (hex) 
Mise Info 
Vial Number: 1 
bundance 
22000 ~ 
20000 
18000 
16ooo I 
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10000 l 
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I A \ 
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V I 
ime--> 16.50 17.00 
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APPENDIXC 
Western Blot of Glycodelin from Two Extracted Tampon Samples. Two tampons 
collected during menses were extracted and analyzed for glycodelin. Protein separation 
and transfer was carried out using SDS-P AGE and western blot. Lane 1 contains the 
reference protein ladder with the approximate molecular weights shown to the left; lanes 
2 and 3 contain unfiltered residue from two tampon extracts, A and B, respectively; lanes 
4 and 5 are concentrated samples A and B, respectively, collected from the Centricon-
Plus 20 protein filter. Lanes 4 and 5 show dark bands near 28kDa, the molecular weight 
of glycodelin. 
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